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Alyssa A. Sprouse 
 
RESVERATROL AUGMENTS PACLITAXEL TREATMENT IN MDA-MB-231 AND 
PACLITAXEL-RESISTANT MDA-MB-231 BREAST CANCER CELLS 
 
Resveratrol has been shown to inhibit cell growth and induce apoptosis, as well 
as augment chemotherapeutics and irradiation in multiple cancer types. However, it is 
unknown if resveratrol is beneficial for treating drug-resistant cancer cells. To study the 
effects of resveratrol in triple negative breast cancer cells that are resistant to the 
common cancer drug, paclitaxel, a novel paclitaxel-resistant cell line was generated from 
the MDA-MB-231 breast cancer cell line. The resulting cell line, MDA-MB-231/PacR, 
exhibited a 12-fold increased resistance to paclitaxel but remained sensitive to 
resveratrol treatment. Resveratrol treatment reduced cell proliferation and colony 
formation and increased senescence and apoptosis in both the parental MDA-MB-231 
and MDA-MB-231/PacR cell lines. Importantly, resveratrol treatment augments the 
effects of paclitaxel in both cell lines. The expression of the drug efflux transporter gene, 
MDR1, and the main metabolizing enzyme of paclitaxel gene, CYP2C8, was increased 
in the resistant cells. Moreover, pharmacological inhibition of the protein products of 
these genes, P-glycoprotein and CYP2C8, decreased paclitaxel resistance in the 
resistant but not in the parental cells, which suggests that the increase of these proteins 
are important contributors to the resistance of these cells. In conclusion, these studies 
imply that resveratrol, both alone and in combination with paclitaxel, may be useful in the 
treatment of paclitaxel-sensitive and paclitaxel-resistant triple negative breast cancers. 
 
Brittney-Shea Herbert Ph.D., Chair 
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CHAPTER 1: INTRODUCTION and LITURATURE REVIEW 
 
I. Breast Cancer 
 
Cancer is a diverse group of diseases that are characterized in general by 
uncontrolled cell growth [1]. Although all cancers involve deregulation of genes that 
control cell growth, there are a wide range of causes and genes involved that are often 
specific to the tissue of origin. Though some of these genetic variations are hereditary, 
90-95% are sporadic [2]. The tissue from which the abnormal cells originate identifies 
cancers though it may spread to many parts of the body, denoting metastatic disease. 
Cancer originating from the breast, known as breast cancer, is the second most 
common cancer and is the fifth cause of cancer deaths in the world [3, 4]. In the United 
States, breast cancer is the second leading cause of cancer death among women [2]. 
One in eight women in the United States will develop breast cancer in their lifetime, and 
of these, approximately fifteen percent will succumb to the disease [5]. It was estimated 
that in 2013 alone more than two hundred thousand women and two thousand men 
would be diagnosed with breast cancer, and more than forty thousand people would die 
from the disease [5]. 
Breast cancers are almost exclusively carcinomas, which derive from epithelial 
cells; breast sarcomas, which derive from mesenchymal cells, are possible, though they 
are rare [6]. Carcinoma breast cancers can be divided into two main types: ductal 
carcinoma in situ (DCIS) and metastatic breast cancer (MBC). DCIS originates from the 
breast duct linings and is a non-invasive cancer, which may or may not ever progress to 
an invasive cancer. It has been suggested that only approximately one-third of DCIS 
cases will progress making the identification of the most likely subtypes to progress 
crucially important [7]. MBCs are cancers that have broken through the ductal or 
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glandular tissue from which they originated and have grown into the surrounding tissue. 
The stage of the disease is important for prognosis and treatment options and is 
determined by three measures: tumor size and distance of spreading within the breast, 
the spread to nearby lymph nodes, and the presence of distant metastases. Staging is 
ranked from 0 to IV with stage 0 being in situ and stage IV being the most advanced 
invasive cancer. Finally, breast cancers are defined by sub-type. Breast cancer sub-type 
is loosely defined by the expression of estrogen receptor (ER), progesterone receptor 
(PR), and whether or not the tumor overexpresses human epidermal growth factor 
receptor 2 (HER2). The luminal A subtype makes up approximately 40% of breast 
cancers and generally consists of ER+ and/or PR+ and HER2- tumors that are slow-
growing and less aggressive [8]. The luminal B sub-type represents 10-20% of breast 
cancers most of which are ER+ and/or PR+ with either overexpression of HER2 or a 
high proliferation rate [8, 9]. The HER2-enriched sub-type is characterized by ER- and 
PR- cancers that overexpress HER2 and are highly invasive and aggressive [8]. Finally, 
10% to 20% of breast cancers are basal-like, which have the worse prognosis of all sub-
types [9]. The majority of basal-like breast cancers are triple negative breast cancers 
(TNBC), which are ER-, PR-, and do not overexpress HER2 [10]. 
There are many known risk factors for breast cancer. The most important risk 
factors for women to develop breast cancer relate to life-long hormone exposure and 
include: menopausal status, the age of menopause and menarche, and time of 
pregnancies. One of the most important risk factor for breast cancers, as for many other 
cancers, is age; risk increases with increasing age. Personal or family history of breast 
cancer is another major factor increasing risk of developing breast cancer. There are 
inherited genetic mutations, such as in the BRAC1 and BRCA2 genes, which increase 
the risk for breast cancer. Although these mutations are only present in 1% of the 
population, it is estimated that 5-10% of breast cancers result from these mutations and 
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so are considered inherited rather than sporadic [11]. Due to knowledge of these risk 
factors, women at high risk for breast cancer can be treated with tamoxifen, an estrogen 
receptor antagonist, or prophylactic surgery to prevent the development of the disease. 
The recent decreases in mortality for breast cancer have been attributed to both early 
detection, promoted by awareness and regular screening, and improvements in 
treatment [12]. 
Treatment options are dependent on the stage and subtype of breast cancer [13]. 
Surgical removal of the tumor is almost always the first treatment for breast cancer; the 
only exception to this is high stage, inoperable tumors that are first treated with 
chemotherapy, known as neaoadjuvant treatment, in an attempt to shrink the tumor and 
to make surgery a treatment option. There are two different options of breast cancer 
surgery: breast-conserving, removal of the tumor only, and total mastectomy, removal of 
all breast tissue. Choice between these surgeries is determined by the stage of disease 
and risk factors present. The treatment that follows surgery is dependent on the surgery 
performed, the stage and the cancer type. DCIS is treated with tamoxifen after a total 
mastectomy and with tamoxifen and radiation therapy after breast-conserving surgery. 
Stage I, II, and some stage III cancers are initially treated similarly to DCIS, but adjuvant, 
or post-surgery, chemotherapy and targeted treatments are added to the possible 
tamoxifen and radiation treatment. The combination of treatments is determined by the 
status of the axillary nodes, sub-type of the cancer, menopausal status of the patient, 
and RNA expression profiling information. More aggressive treatment is necessary in 
axillary node- positive and pre-menopausal patients. For the remaining stage III and all 
stage IV cancers, many tumors are inoperable. Treatment often includes hormone 
therapy, targeted therapies and chemotherapy simultaneously. Radiation therapy and 
surgery are also important parts of treatment though the timing of these treatments is 
less clear than in lower staged cancers. 
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For patients with TNBC, surgery along with radiation and traditional 
chemotherapy are the standard of care as discussed above. However, although great 
strides have been made over the last decade with targeted therapies, therapies that 
directly target ER and HER2, these therapies are ineffective in TNBCs, which lack ER 
and do not overexpress HER2. Due to the lack of targeted therapies, these patients 
have a poor prognosis [5]. 
 
A. Triple Negative Breast Cancer (TNBC) 
 
TNBCs are associated with lower survival rates than other breast cancers [14].  
Partially this is due to the recently decreased mortality rates of other breast cancers 
resulting from improvements of treatments that are not available to patients with TNBCs. 
Interestingly, pathologically complete response rates are higher in triple negative 
compared to other breast cancer sub-types [15]. However, TNBCs are highly aggressive 
and more likely than other sub-types to recur which result in lower survival rates [16]. A 
common measure of the aggressiveness of cancer is the differentiation status. Cancers 
that are not well differentiated, or look very different from the tissue of origin cells, tend 
to grow much faster and therefore spread faster [17]. TNBCs are much more likely to be 
poorly differentiated or undifferentiated compared to other breast cancers [18]. 
TNBCs are also associated with younger age and more advanced stage at 
diagnosis. In addition, TNBCs are more common and have worse prognosis among 
African Americans and Hispanics compared to other ethnic groups [18]. Some of this 
health disparity is undoubtedly due to differences in access to medical care, treatment or 
socioeconomic status [19-21]. However, it has been shown that access to medical care 
cannot completely remove this disparity [22-24], and there is a biological disadvantage 
for survival in African American women [10, 25, 26].  
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There are several active areas of research working toward improved treatments 
for TNBCs. The use of platinum agents in combination with standard therapy is currently 
being studied in cancers that have a mutation in BRCA1, a gene important in double-
strand DNA break repair, as these cancers cannot repair the damage to DNA caused by 
platinum agents [27, 28]. This may be a promising treatment regimen in TNBCs as 
cancers with BRCA1 mutations are often TNBCs. PARP inhibitors have also shown 
some success, but will possibly only work in BRCA1 and BRCA2 mutant cancers as they 
rely on synthetic lethality, which is the targeting of multiple pathways that would 
compensate if only one were targeted [29, 30]. An anti-epidermal growth factor receptor 
(EGFR) antibody has also been attempted, though the response rate was only 20% as 
the EGFR pathway was deactivated by the treatment in only 25% of the cases 
suggesting compensating mechanisms [31]. In addition, there is promise in the use of 
anti-angiogenic therapies for TNBCs [32, 33]. While all of these approaches are currently 
in clinical trials, none of these have yet made it to the clinic. 
Due to health disparities, poor prognosis and lack of treatments, more research 
needs to be done to improve the treatment of TNBCs. In addition to these problems, 
resistance to chemotherapy is a concern for all cancers. However, in TNBCs, which rely 
entirely on chemotherapy treatment, drug resistance is of even larger concern. Though 
the pathologically complete response rate is high in TNBCs at 22%, the prognosis for 
cancers that do not respond to chemotherapy is very poor [34]. This suggests a high 
level of intrinsic resistance. Interestingly, approximately one third of metastatic breast 
cancer patients with intrinsic taxane resistance are patients with TNBCs [35]. 
Furthermore, the high rate of recurrence among TNBCs suggests an increased 
opportunity for acquired multi-drug resistance. 
 
 
6 
 
B. Cancer Drug Resistance 
 
Cancer drug resistance limits the effectiveness of chemotherapeutics. It is 
estimated that 90% of treatment failure in metastatic cancers is due to drug resistance 
[36]. There are two different types of drug resistance: intrinsic and acquired [37]. Intrinsic 
drug resistance denotes that treatment is ineffective because resistance-mediating 
factors were already present in a tumor prior to treatment. Acquired resistance develops 
during treatment by adaptive responses or mutations in a previously sensitive tumor; 
resistance can also be acquired by the selection of a resistant population of cells, which 
can cause recurrence. 
There are many known mechanisms of cancer drug resistance (Figure 1). Many 
mechanisms affect the balance of drug entry and exit to prevent drug accumulation, as 
accumulation of chemotherapeutics in cells is crucial for drugs to bind to their molecular 
targets. Cancer cells can alter drug accumulation by inhibiting drug uptake or, more 
commonly, increasing drug efflux. However, there are other ways of achieving a 
decrease of drug that is free to bind to molecular targets such as compartmentalizing the 
drug away from the target or altering drug metabolism so the active form of the drug is 
not available. Aside from drug availability, alteration of drug targets, DNA damage repair 
mechanisms and cell crisis response mechanisms can all lead to cancer cell survival. 
Increases in drug targets may allow cancer cells to compensate in the presence of a 
drug. In addition, the mutation of a drug target that inhibits drug binding can render a 
drug ineffective. Cancer cells are well known to hijack endogenous mechanisms to 
promote survival. A cancer cell that is capable of repairing DNA damage efficiently may 
be resistant to drugs that directly cause DNA damage. In addition, cancers that have 
hijacked cell cycle arrest or apoptosis pathways may be capable of escaping the cell 
death that chemotherapeutics should cause. 
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Figure 1. Mechanisms of Cancer Drug Resistance. Possible mechanisms by which 
cancer cells can evade drug-induced cell death. Resistance in cells may be a single 
mechanism or a combination of mechanisms (D=Drug; D*=Drug metabolite). Originally 
published in [38]. 
 
Due to toxicity to normal cells, doses of chemotherapeutics may be limited, which 
rules out any possibility of simply giving more drug to overcome some of these 
resistance mechanisms. However, there are several methods to overcome resistance to 
a drug [39]. Treating with a different drug to which the cells are sensitive is a simple 
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approach. However, many drug resistance mechanisms can cause multidrug resistance, 
conferring resistance to multiple drugs, limiting this approach. To avoid this problem, 
patients are standardly treated with a “cocktail” of chemotherapy drugs providing multiple 
drugs at once with different modes of entry and cellular targets and so a multiple hit 
approach, maximizing cancer cell killing. Another possibility to overcoming drug 
resistance is combining chemotherapy with another drug that will make the cells more 
sensitive to the original drug or otherwise enhances the effect of the chemotherapeutic. 
These combination therapies are molecularly targeted to improve response to 
chemotherapeutics and have shown varying levels of success [37]. 
It is important to study resistance of specific drugs in specific cancers as both 
factors impact the development and, therefore, the reversion of drug resistance. One of 
the first line treatments for breast cancer is the mitotic inhibitor from the taxane drug 
class, paclitaxel. Paclitaxel is a very successful drug; however, some breast cancers are 
intrinsically resistant and others can acquire resistance to the drug. Consequently, there 
is a need for methods to overcome paclitaxel resistance particularly in TNBCs, which 
rely heavily on chemotherapy treatment. 
 
II. Paclitaxel 
 
Taxanes are a class of microtubule-stabilizing agents or mitotic inhibitors [40]. 
Microtubules are protein polymer filaments, which are important in cellular functions 
such as cell shape, movement, signaling, division and mitosis [41]. These filaments are 
hollow cylinders made up of α and β tubulin heterodimers and display dynamic instability 
and treadmilling behavior [42]. Dynamic instability is the process of constant lengthening 
and shortening of the microtubules by the association and dissociation of α/β tubulin; this 
process can be held in stead state by balancing the lengthening and shortening of the 
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microtubules or can be overpowered by one or the other causing an imbalance in the 
process [41, 43, 44]. Treadmilling describes the lengthening of one end of the tubule 
concurrent with the shortening at the other end [45]. These processes occur in all cells 
and are regulated by microtubule-associated proteins (MAPs) such as tau, which binds 
and stabilizes microtubules [46]. The dynamic polymerization and depolymerization of 
microtubules is essential for cell division and chromosome segregation during mitosis 
[43]. Taxanes bind to β-tubulin on a site that is only accessible when tubulin is 
assembled [42, 47, 48]. When taxanes are bound to assembled tubulin, they suppress 
microtubule dynamics by stabilizing the microtubule and preventing disassembly [41]. 
This stabilization prevents the cells from undergoing mitosis and induces mitotic 
catastrophe and apoptosis [41, 49]. 
The first drug in the taxane family to be discovered, paclitaxel, was first isolated 
in 1969 from the bark of the pacific yew tree (Taxus brevifolia) [50]. After decades of 
improving synthesis methods, Taxus species cell cultures are now used with elicitor 
compounds to produce paclitaxel [51]. However, the difficulty of producing paclitaxel 
continues to create a shortage of the drug [52]. Intravenously administered paclitaxel 
presents nonlinear pharmacokinetics, is metabolized in the liver and is eliminated 
through the biliary system [53, 54]. Due to the high hydrophobicity of paclitaxel, it must 
be administered in a formulation of alcohol and Cremophor ® EL (polyoxyethylated 
castor oil) to assist delivery; this formulation can cause severe hypersensitivity reactions; 
though, the frequency of these reactions has been reduced with shorter infusion times 
and premedication with corticosteroids and anti-histamines [52]. In addition, paclitaxel 
has severe side effects such as neutropenia and neuropathy that significantly limit 
dosage [55]. However, paclitaxel can be administered with acceptable toxicity and is still 
considered a successful treatment for non-small-cell lung, ovarian and breast cancers in 
some patients [56-58]. 
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Paclitaxel is a first-line treatment for breast cancer and has a response rate 
between 25 and 69% [59]. Paclitaxel can be given as a single agent but is often given in 
combination with an anthracycline, such as doxorubicin, as it improves disease-free 
survival and overall survival [60, 61]. In addition, paclitaxel is often given with an 
anthracycline and an alkylating agent, such as cyclophosphamide [62]. Paclitaxel given 
as a 1-hour infusion weekly, rather than as a 3-hour infusion every 3 weeks, improves 
both disease-free survival and overall survival [63]. For HER2 positive breast cancers, 
neoadjuvant paclitaxel and doxorubicin followed by cyclophosphamide, methotrexate, 
and fluorouracil given in combination with adjuvant and neoadjuvant trastuzumab, a 
HER2 inhibitor, improves clinical and pathological response by 22% [64]. Paclitaxel is 
currently in a clinical trial, CALGB-40603 (NCT00861705), in TNBCs to evaluate 
neoadjuvant chemotherapy combination of carboplatin with the standard paclitaxel and 
doxorubicin plus cyclophosphamide treatment. Although paclitaxel is an efficacious drug, 
resistance is a problem as with all cancer drugs tested to date. 
 
A. Paclitaxel Resistance in Breast Cancers 
 
Both intrinsic and acquired taxane resistance are common in cancers [45]. There 
are many mechanisms of paclitaxel resistance that have been previously shown to 
potentially be relevant in breast cancers. Importantly, though all of these mechanisms 
have been seen in vitro, none have yet been convincingly shown to be a clinically 
relevant mechanism of paclitaxel resistance in breast or any other cancer with the 
exception of the up-regulation of multidrug resistance proteins [65, 66]. Due to this 
clinical relevance, the up-regulation of multidrug resistance proteins is of particular 
importance and will be discussed at length. In addition, the next most likely mechanism 
to be relevant to resistance is changes in drug metabolism, which will also be discussed 
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at length. Resistance through drug target alteration has been shown with mutations in 
the paclitaxel target protein, β-tubulin [67-69]. In addition, changes in the expression 
profile of the seven different β-tubulin isotypes can affect paclitaxel action as isotypes 
βIII and βIV require more bound paclitaxel to stabilize the microtubule [70]. Variation of 
the expression of MAPs, which regulate microtubule dynamics, can also confer 
resistance to paclitaxel. Examples are high levels of microtubule stabilizing proteins, 
such as tau and stathmin, or low levels of destabilizing proteins, such as MAP4 [71-73]. 
Deregulation of the cell cycle, specifically in the spindle assembly checkpoint, and 
associated proteins can also lead to resistance [74-79]. Furthermore, changes in levels 
of apoptosis-related proteins such as p53, Bcl-2, Bcl-xL, Akt, survivin, XIAP, and NFκB 
to inhibit apoptosis can cause resistance [80-85]. The upregulation of HER2 can also 
confer paclitaxel resistance, which seems to show some clinical significance in the 
beneficial effect of combining trastuzumab with paclitaxel [86]. It is important to note that, 
for the present work, the upregulation of HER2 and the changes of p53 will not be 
mechanisms of concern, as the cell line used in this study does not overexpress HER2 
and harbors mutant p53 protein. Though HER2 overexpression would not be an 
important clinical factor for TNBCs, it is possible that changes in p53 could be important 
clinically for TNBCs that harbor wild-type p53 protein. Importantly, most of these 
mechanisms have yet to be shown to have clinical relevance with the exception of 
multidrug resistance proteins and the alteration of drug metabolism, which are the most 
likely candidates for a resistance mechanism 
 
B. Multidrug Resistance Proteins 
 
ATP binding cassette (ABC) proteins are transporters that utilize ATP to transport 
a specific substrate or group of substrates across the cell membrane. Substrates for 
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these proteins can be metal ions, sugars, amino acids, peptides, proteins, hydrophobic 
compounds and metabolites [87]. These transporters are believed to operate by 
alternating access from one side of the membrane to the other by a conformational 
change [88]. ATP hydrolysis provides the energy to switch the protein from facing inside 
the cell when a substrate is bound to outward facing to then release the substrate. Drug 
interactions are a possibility for transporters with multiple substrates as substrates can 
act as competitive inhibitors [38]. ABC transporters that transport cancer drugs have 
been shown to be important in resistance by preventing cancer drug accumulation in 
cells. There are 48 known human ABC genes that are separated into seven distinct 
subfamilies based on organization of domains and amino acid homology which leads to 
differences in substrate specificity [87]. For example, the MDR proteins transport a 
variety of hydrophobic compounds whereas the MRP proteins transport organic anions, 
such as glutathione conjugates of compounds [87]. P-glycoprotein (P-gp, MDR1, 
ABCB1), BCRP (ABCG2), and MRP2 (ABCC2) have all been shown to be widely 
expressed in tumors and linked to drug resistance [89, 90]. The ability to inhibit these 
proteins has the potential to greatly improve chemotherapy treatment and so have been 
studied for many years [91]. 
P-gp was the first ABC efflux pump to be identified and has been studied 
extensively. P-gp is located on chromosome 9q31.1 and is ubiquitously expressed, 
though it is most prominently expressed in the liver and blood-brain barrier. P-gp is a 
highly promiscuous transporter, which binds electrically neutral and positively charged 
hydrophobic drugs [38]; hundreds of substrates have been identified, including several 
chemotherapeutics [89, 90]. It has been shown that treatment with several anti-cancer 
drugs in colon cancer cells can induce pregnane X receptor, which induces P-gp 
expression and decreases drug accumulation [92]. In addition, inhibition of P-gp has 
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been shown to restore drug sensitivity to resistant cells in culture that overexpress the 
protein [93]. 
Notably, paclitaxel is a substrate of P-gp, and P-gp has been implicated in 
paclitaxel resistance in breast cancer [94]. The analysis of 60 cells lines revealed that 
the lower the P-gp gene expression, the higher the sensitivity to paclitaxel [95]. In cell 
lines derived from breast carcinoma specimens, a similar correlation between high P-gp 
expression and high paclitaxel resistance was also shown [96]. P-gp is expressed in 
normal breast tissue, though usually in lower levels than in in cancer tissue [97]. 
Approximately 40% of untreated breast cancers express P-gp compared to 52% of 
cancers that have been treated with a P-gp substrate [97]. Interestingly, the level of P-gp 
positive cancers is higher in cancers within one month post-treatment at 56% compared 
to only 36% of cancers more than one month post-treatment suggesting that the effect of 
chemotherapy is transient [97]. Perhaps most striking is a comparison of tumors pre- 
and post-neoadjuvant treatment; only 43% of tumors were positive for P-gp prior to 
treatment compared to 64% positive afterward, which is a 37% induction of P-gp 
expression [97]. High expression of P-gp has been associated with poor response of 
locally advanced breast cancer to neoadjuvant chemotherapy, though the therapy in 
these studies did not include paclitaxel [98, 99]. Of critical importance, tumors with high 
P-gp expression demonstrate faster drug clearance and lower drug accumulation in the 
tumor [100-105]. 
Thus far, no P-gp inhibitors have made it to clinical use in combination with 
chemotherapeutics, though many clinical trials have been conducted with various 
inhibitors and chemotherapy regimens. When pooled, four studies of the P-gp inhibitor 
verapamil in advanced breast cancer patients refectory to anthracycline-containing 
treatment regimens, showed 15% re-sensitization [97]. However, later studies proved 
verapamil to have a dose limiting and life-threating cardiotoxicity [106]. The P-gp 
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inhibitor, biricodar, showed a partial response of 11% in combination with paclitaxel in 
locally advanced breast cancer patients refractory to paclitaxel [107]. Two other 
inhibitors, zosuquidar and tariquidar, have shown disappointing clinical results in breast 
cancer suggesting there may be redundancy in efflux pumps that must be addressed 
[37, 108, 109]. Recently the importance of the dynamics between P-gp and the 
membrane has become apparent, which may lead a new generation of inhibitors [91]. In 
summary, although there have been only minor clinical successes in reversing drug 
resistance with P-gp inhibitors, P-gp remains an important potential target to re-sensitize 
breast cancers that are refractory to or likely to be resistant to paclitaxel treatment as P-
gp has been shown to be an important factor in tumors and targeting of P-gp can 
reverse some clinical drug resistance. 
 
C. Drug Metabolism 
 
Drug metabolism is separated into three phases although not all drugs have to 
go through all phases. Phase I metabolism reactions are often catalyzed by cytochrome 
P450 (CYP) enzymes and include oxidation, reduction, hydrolysis, cyclization, or 
decyclization reactions. Some of the resulting polar metabolites can be excreted at this 
point. Otherwise, the metabolite will have to undergo a phase II metabolism reaction, 
which include methylation, sulfation, acetylation, glucuronidation, glutathione 
conjugation, or glycine conjugation, catalyzed by a transferase to produce highly polar 
conjugate molecules that are usually less active and must be actively transported due to 
the addition of large anionic groups [110]. In phase III metabolism, these conjugates can 
be further metabolized and excreted from cells by ABC transporters with the anionic 
groups acting as an affinity tag for the transporters [111, 112]. Outside of the cell the 
conjugates and metabolites are either further metabolized or excreted [113]. 
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CYP enzymes are a family of mono-oxygenases, which catalyze organic 
substance oxidation. Most commonly, CYPs insert one oxygen atom into the aliphatic 
position of an organic substrate and reduce the other oxygen atom to water [114]: 
RH + O2 + NADPH + H+ → ROH + H2O + NADP+ 
Generally membrane-associated proteins , human CYPs are located primarily in the 
endoplasmic reticulum but can also be located in the inner membrane of the 
mitochondria or the plasma membrane [115]. These enzymes are present in most 
tissues, though the expression is specific to each CYP and its function [116]. CYPs can 
play important roles in the formation and metabolism of lipids, steroids or xenobiotic 
substances such as toxic chemicals and drugs and may metabolize one, few or many 
substrates [117]. Total CYP activity accounts for approximately 75% of total drug 
metabolism [118]. Although some drugs can be activated by this metabolism, most drugs 
are deactivated by CYPs. 
Changes in drug metabolism mechanisms in cancer cells can play a role in drug 
resistance [36, 37]. For drugs that must undergo metabolism for activation, a decrease in 
metabolism will decrease the amount of active drug available inside cells rendering the 
cells more resistant to the drug. More commonly drugs are inactivated by metabolism, 
and with an increase of metabolism there is a decrease in the amount of active drug 
available to bind to intracellular targets. Therefore, a decrease or increase of metabolism 
enzyme expression or activity could affect how cancer cells react to drugs. Changes in 
these enzymes can lead to cancer drug resistance or higher sensitivity to drugs. 
Therefore, manipulating these mechanisms with combination therapies provides a 
strategy for overcoming drug resistance. Conversely, it is also possible that drug 
combinations could dangerously increase drug toxicities. Importantly, this makes the 
study of individual drug metabolism pathways in individual cancers important to 
overcoming cancer drug resistance as well as predicting harmful drug-drug interactions.  
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Paclitaxel has two main metabolites in humans: 6α-hydroxypaclitaxel (6α-OHP) 
and C3’-hydroxypaclitaxel (C3’-OHP) (Figure 2). 6α-OHP is formed by CYP2C8 and C3’-
OHP is formed by CYP3A4 [119]. 6α-OHP has been shown to be 30-fold less active than 
paclitaxel [120], and C3’-OHP shown to have no activity [121]. 6α-OHP is the most 
important metabolite making up approximately 60% of excreted paclitaxel compared to 
only 10% of C3’-OHP [122]. There is one other metabolite, which has very low 
abundance and was originally reported to be di-hydroxypaclitaxel [123] but was shown in 
a later study to be C2-hydroxypaclitaxel formed by CYP3A4 [124]. It has also been seen 
that induction of CYP3A4 due to concomitant drug use can change the metabolite profile 
of paclitaxel in a patient [54]. Crucially, it has been shown that it is possible for drug 
interactions to affect CYPs and, therefore, the efficacy of paclitaxel [125]. Enhanced 
ability of a cell to metabolize paclitaxel would protect a cell from the toxic effects of 
paclitaxel, and due to the larger contribution of CYP2C8 in paclitaxel metabolism it is 
likely that this enzyme would be of greater importance. Consequently, overexpression of 
CYP2C8 in a cancer cell could explain a high tolerance for paclitaxel and so confer 
resistance. 
 
 
 
 
 
 
Figure 2. Metabolism of Paclitaxel in Humans. The major metabolism pathway through 
CYP2C8 produces 6α-hydroxypaclitaxel, a 30-fold less active metabolite. The 
metabolites produced by CYP3A4 are inactive and much less abundant. Adapted from 
[124, 126]. 
Paclitaxel 
6α-hydroxypaclitaxel C3’-hydroxypaclitaxel 
CYP2C8 CYP3A4 
C2-hydroxypaclitaxel 
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The CYP2C8 gene is located on chromosome 10q24 along with the other 
CYP2C family members [127]. The CYP2C8 gene has several polymorphisms, and 
though the high inter-individual variability in paclitaxel pharmacokinetics is well known 
[128], it has yet to be strongly linked to CYP2C8 polymorphisms [129]. Interestingly, it 
has been suggested that the lack of consensus on a link between paclitaxel 
pharmacokinetics and CYP2C8 polymorphisms may be due to the lack of studies that 
simultaneously consider polymorphisms of ABCB1 and CYP2C8. CYP2C8 protein is 
highly expressed in the human liver making up approximately 7% of the total microsomal 
CYP content [130, 131]. CYP2C8 has many endogenous and exogenous substrates and 
carries out the phase I oxidative metabolism of at least 5% of drugs cleared by the liver 
[132]. CYP2C8 metabolizes drugs in several drug classes such as thiazolidinediones, 
meglitinides, NSAIDs, anti-malarials and taxanes; CYP2C8 is often a secondary 
mechanism of metabolism, but it can be the primary mechanism, as it is with paclitaxel, 
choloroquine, rosiglitazone and repaglinide [129]. In addition to the liver, CYP2C8 mRNA 
has been shown to be expressed in several other tissues including the kidney, intestine, 
adrenal gland, brain, mammary gland, ovary, heart and, notably, in breast cancer tumors 
[116, 133-136]. Importantly, overexpression of CYP2C8 has been shown to contribute to 
acquired paclitaxel resistance by increasing paclitaxel metabolism in colon cancer cells 
with no contribution of CYP3A4 [137]. Taken together, these data suggest alteration of 
paclitaxel metabolism may be an important mechanism of paclitaxel resistance in breast 
cancers. 
 
III. Dietary Supplements 
 
Complementary and alternative medicine (CAM) encompasses a wide range of 
health treatments that are not used in conventional medicine and are often supported by 
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little or no scientific evidence. In western countries, 40-50% of all cancer patients use 
some type of CAM [138, 139]. The most common user is female, highly educated and of 
high socioeconomic status. Therefore, the most prevalent CAM users are women with 
breast cancer [139, 140]. There are many reasons for people to choose CAM therapies; 
stress reduction, decreasing side effects, improving strength and the immune system, 
the desire of a ‘more holistic’ treatment and autonomy are all important factors reported 
[139, 141-145]. In addition, many hope to prevent cancer recurrence or to fight cancer 
directly. CAM therapies present many problems, which are confused by the fact that very 
few people disclose their CAM use to their oncologists [146, 147]. CAM therapies can 
cause side effects of their own accord, but they can also cause dangerous drug 
interactions. Perhaps the most dangerous problem for cancer patients is the postponing 
or omission of proper treatment. Finally, CAM therapies can have a large financial 
impact on both individuals and health care systems. 
Several of the most common CAMs used by breast cancer patients fall into the 
dietary supplements category [148]. The category of dietary supplements encompasses 
a range of products from vitamins to botanicals. In the United States, dietary 
supplements are a multi-billion dollar per year industry [149]. The use of dietary 
supplements has been steadily rising in the United States. One study in 2002 showed, 
14% of the general population and 16% of prescription drug users concurrently take 
some kind of dietary supplement [150]. In 2005, it was estimated that the prevalence of 
botanicals use in the United States is approximately 12.1-18.6% [151]. However, by 
2011 it was reported that 50% of Americans reported using dietary supplements, and 
approximately 20% of adults were using botanicals [152]. Importantly, dietary 
supplements are not regulated like foods or drugs but instead fall under the Dietary 
Supplement Health and Education Act of 1994, which restricts the authority of the FDA 
over these products [153]. Therefore, many of these products have been insufficiently 
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tested for safety, efficacy and often quality control. Though viewed by the public as 
generally safe, there are many examples of botanicals causing harmful herb-drug 
interactions [154]. 
However, botanicals can also have beneficial health effects and provide the basis 
of many medications. It is estimated that from 1 in 3 to 1 in 2 of currently used drugs 
were derived from plants [155]. Indeed, over 60% of clinically used anti-cancer agents 
are derived from natural sources such as plants, marine organisms and microorganisms 
[156]. Vinblastine and vincristine were discovered in the 1950s, which spurred an 
extensive program initiated by the National Cancer Institute in 1960 producing most of 
these discoveries including taxanes and camptothecins. However, since these 
compounds have reached the clinic, no other plant-derived anti-cancer agents have 
made it to general use [156]. 
To conclude, botanicals and their derivatives have the potential to be both 
harmful and beneficial alone and in combination with prescription drugs. Considering 
that women with breast cancer are the most common CAM users, more research is 
needed to ensure the safety of patients taking botanicals. In addition, in light of the need 
for more treatments, especially for TNBCs, more research is needed to determine if any 
of these botanicals or their derivatives can improve treatments. Resveratrol is a highly 
studied, botanically derived chemical of particular interest, which has been shown to 
have a wide variety of health effects. 
 
IV. Resveratrol 
 
Resveratrol is made by a variety of plant species in response to fungal infection 
or exposure to ultraviolet light, and therefore classified as a phytoalexin [157]. Assaults 
cause a hormone response in plants, which induces gene expression of resveratrol 
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synthase to produce resveratrol [158]. Resveratrol functions as a plant pathogen toxin as 
well as and inducer of plant cell death when stress cannot be counteracted [159]. Due to 
widespread production in plants it is also present in the human diet though in very low 
amounts and is perhaps best known to be in grapes, peanuts and red wine [160]. 
Resveratrol is a polyphenol and a stilbenoid, a chemical with a stilbene backbone 
(Figure 3). Highly lipophilic and insoluble in water, resveratrol is highly soluble in ethanol 
and DMSO and so many studies are performed using one of these solutes [161]. It is 
stable in solution and human plasma with the exception of extended exposure to light or 
high pH environments [162]. 
 
 
 
 
 
 
 
Figure 3. Chemical Structure of Resveratrol. Trans-3,4’,5-trihydroxystilbene is a highly 
lipophilic polyphenol stilbenoid. 
 
Resveratrol is being studied for prevention or delaying progression of aging, 
cardiovascular diseases, neurodegenerative diseases, as well as cancer prevention and 
treatment [163]. Generally, the protective effects are produced with low nanomolar to 
micromolar concentrations of resveratrol whereas anti-cancer effects are produced with 
high micromolar concentrations. This biphasic effect of resveratrol coincides with 
previous work showing that cancer cells treated with low concentrations of resveratrol 
increase proliferation compared to higher concentrations that cause cancer cell death 
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[164]. The anti-oxidant and anti-inflammatory effects of resveratrol seem to be important 
factors for the beneficial cardiovascular, neuroprotective, and anti-aging effects [163]. 
Resveratrol demonstrates protective effects at low μM concentrations in relation to 
multiple neurodegenerative disorders, which are a group of progressive disorders 
sharing inflammatory status and accumulation of reactive oxygen species causing 
neuron damage and death such as Alzheimer, Parkinson and Huntington Disease. The 
anti-inflammatory effects, reduction of oxidative stress, inhibition of apoptosis, and 
effects on neurological function are all important in neurodegenerative disease 
protection effects of resveratrol [163]. There are many targets that have been shown to 
be important in these actions many of which are also important in the cardioprotective, 
anti-ageing and anti-cancer effects. Of particular interest is the involvement of the 
activation of SIRT1 through the AMPK pathway, which is also important for the 
cardioprotective effects [163]. For resveratrol-induced chemoprevention, regulation of 
carcinogen metabolism as well as cell proliferation inhibition and apoptosis induction are 
important [165]. Resveratrol has been shown to prevent or delay the onset of cancer 
[166, 167]. In breast cancer, resveratrol has been shown to exhibit anti-initiation, anti-
promotion and anti-progression activities in both hormone-sensitive and hormone-
resistant breast cancers [168]. These effects of cancer prevention seem to be related to 
xenobiotic metabolism regulation as well as anti-inflammatory, anti-proliferative and pro-
apoptotic effects [168]. Details of anti-cancer activity of resveratrol will be discussed at 
length below. Despite extensive pre-clinical work with resveratrol, human safety and 
efficacy studies are scarce [169]. However, many studies have been conducted 
attempting to elucidate the metabolism and complicated pharmacokinetics of resveratrol 
in humans. 
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A. Resveratrol Pharmacokinetics 
 
Resveratrol is metabolized very rapidly in humans [170]. Free resveratrol and its 
metabolites are both highly bound to plasma proteins, which would suggests poor 
availability [171]. However, it has been shown that protein-bound resveratrol can still be 
transported into cells as free resveratrol through carrier-mediated transport [172]. The 
predominate metabolites consist of two sulfated and two glucuronidated forms, 
Sulfotransferases form the sulfated metabolites, and glucuronidated metabolites are 
formed by the UDP-glucoronosyltransferases 1A family [173]. In humans, the sulfated 
metabolite, resveratrol-3-O-sufate, is the most prominent [174]. Importantly, resveratrol 
metabolites have shown little or no anti-cancer activity with the exception of some 
resveratrol sulfates showing low cytotoxicity in breast cancer cells and one study 
showing activity in colon cancer cells [175-178]. However, physiologically relevant 
amounts of sulfate metabolites have been shown to be regenerated into resveratrol and 
cause cell proliferation inhibition of cultured colon cancer cells through autophagy and 
senescence [178]. Therefore, it is likely that any effects of resveratrol treatment are due 
to resveratrol activity and not the activity of metabolites. 
Resveratrol is very well tolerated in humans [179]. After 8 days of daily oral 
resveratrol dosing in healthy volunteers, no toxicities presented with up to 1 gram per 
day, and only mild gastrointestinal toxicities were observed with 5 grams per day. The 
half-life of resveratrol has been seen to vary from 2.9 to 11.5 hours [180]. A seemingly 
poor oral bioavailability, which has been attributed to poor intestinal absorption or 
extensive intestinal metabolism, has been a major barrier to the potential clinical use of 
resveratrol [181-184]. However, resveratrol demonstrates high intestinal absorption, as 
approximately 70% enters enterocytes by passive diffusion in humans [185]. In rodents it 
has been shown that resveratrol is highly metabolized in the enterocytes, and MRP2 and 
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BCRP, but not P-gp, then excrete the resveratrol metabolites back into the intestinal 
lumen limiting intestinal absorption [186, 187]. In addition, resveratrol is highly excreted 
in urine, and has highly variable excretion in feces, which suggests the occurrence of the 
enterohepatic cycle [185]. Enteric recirculation is further supported by a secondary peak 
in resveratrol plasma concentration at 6 hours following the primary peak at 1 hour [185]. 
Interestingly, although resveratrol excretion shows high inter-individual variability, all the 
subjects had a portion, between 2 and 30%, of resveratrol that was not recovered in 
either the urine or feces; the fate of which was unknown. These phenomena create a 
confusing picture of resveratrol pharmacokinetics, which has spurred interest in 
resveratrol analogues and drug delivery systems to improve bioavailability. 
The problem of bioavailability has been especially troubling for the anti-cancer 
effects of resveratrol that only occur at high micromolar concentrations. However, 
recently a series of studies have emerged suggesting that bioavailability may not be as 
major of a problem as once believed. Previously, plasma levels of resveratrol and its 
metabolites have been shown to be very low with gram doses resulting in only low 
micromolar amounts in plasma [170]. However, a new study has shown plasma 
concentrations of resveratrol metabolites in humans to be higher than previous 
estimations due to a lack of metabolite standards [178]. Critically, this study showed in a 
mouse model that the sulfated metabolite of resveratrol, which has the highest plasma 
concentrations of all the resveratrol forms, enters cells and can be converted back to 
free resveratrol. The uptake of the sulfate metabolite is likely dependent on anion 
transporter SLC22A9 and anion-transporting polypeptides SLCO1B1 and SLCO1B3 
[178]. This mechanism of resveratrol regeneration resulted in a sustained exposure to 
resveratrol and suggests that resveratrol can be regenerated from conjugates as long as 
they are present, which can be at least 24 hours [174]. At 1 gram of resveratrol per day, 
20 to 30 μM concentrations of resveratrol sulfates can be attained in human plasma, 
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which is within the range of inhibiting cell proliferation in cancer cells [179]. When 
resveratrol and resveratrol metabolite levels were measured in the colorectal tissue of 
colon cancer patients, resveratrol was shown to have accumulated to high micromolar, 
up to 640 μM, amounts [188]. Although there has been considerable interest in 
developing resveratrol analogs and delivery systems to promote delivery of efficacious 
concentrations to target tissues, these studies suggest these extra efforts may not be 
necessary. 
 
B. Resveratrol Anti-cancer Pharmacodynamics 
 
The anti-cancer effects of resveratrol have been extensively studied in many in 
vitro and in vivo human cancer models. Resveratrol has been shown to inhibit 
angiogenesis, invasion and metastasis, and cell proliferation and to induce cell cycle 
arrest and apoptosis in various cancers [189, 190]. Interestingly, many of the effects of 
resveratrol appear to be cell type specific. For example, the type of cell cycle arrest 
caused by resveratrol, if any, is dependent on cancer cell-type [161]. Additionally, due to 
phytoestrogen properties, resveratrol may stimulate growth in breast cancers that 
express ER [191]; however, this effect has been contested [192]. This contradiction may 
be explained by low resveratrol concentrations inducing proliferation whereas high 
concentrations suppress proliferation [193]. Finally, resveratrol has been shown to cause 
senescence, an essentially irreversible form of cell proliferation arrest [194], and 
autophagy, the effect and relevance of which is unclear [195], in various cancer cells 
[196]. Autophagy is a multistep process in which autophagolysosomes are formed so 
cells can destroy proteins or damaged organelles; this process is normally used by cells 
to promote survival during stress, however, it can also cause cells to undergo cell death 
[197]. Although resveratrol inhibits proliferation and induces cell death in many cancer 
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cells, the mechanisms through which resveratrol acts vary widely [161] (Figure 4). Some 
of the pathways resveratrol has been commonly shown to inhibit are the NF-κB, MAPK, 
and AP-1 pathways [161]. Resveratrol has also been shown to activate other pathways 
such as the p53 and FAS pathways [161]. In addition, resveratrol has extensively been 
shown to suppress protein kinases, growth factors, cell-cycle proteins as well as COX-2 
and lipooxygenase [161]. Recently, evidence has shown that resveratrol has the ability 
to target cancer stem cells, which are capable of self-renewal and differentiation and are 
believed to the root of tumor heterogeneity [198], through inhibition of fatty acid synthase 
[199], inhibition of pluripotency maintain factors and epitherlial-mesenchymal transition 
[200, 201] and metabolic reprogramming [201]. With so many varied effects caused by 
resveratrol, it is important to study the effects of resveratrol in different cellular 
backgrounds. 
A wide variety of resveratrol effects have been seen even within TNBC cell lines. 
In MDA-MB-468 cells, resveratrol inhibited TGF-α, PC-cell derived growth factor and 
insulin-like growth factor 1 receptor mRNA expression and increased TGF-β mRNA 
[202]. In the 4T1 triple negative cell line, resveratrol inhibited proliferation in culture, but 
in mice no inhibition of growth or metastasis was seen [203]. Most TNBC data has been 
obtained using MDA-MB-231 cells. Proliferation inhibition by resveratrol in MDA-MB-231 
cells has been attributed to a decrease of reactive oxygen species [204]. Resveratrol 
has been shown to cause non-apoptotic cell death in MDA-MB-231 cells by decreasing 
expression and kinase activities of positive G1/S and G2/M cell cycle regulators and 
inhibiting ribonucleotide reductase activity with no effect on the low expression of p21, 
p27 or mutant p53 levels and causing no cell cycle arrest [205]. In another study, 
apoptosis was seen in MDA-MB-231 and attributed to an induction and increased 
nuclear localization of COX-2; this study also saw an increase of p53 phosphorylation 
though the significance of this is unclear considering the mutant status of p53 in these 
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cells [206]. However, resveratrol-induced proliferation inhibition and apoptosis in MDA-
MB-231 cells has also been attributed to an increase of serine palmitoyltransferase and 
neutral sphingomyelinase leading to ceramide accumulation [207]. Resveratrol has also 
been shown to inhibit the promoter activity of NF-κB, a transcription factor often 
constitutively active in cancer cells, in a dose dependent manner in MDA-MB-231 cells 
[208]. Notably, resveratrol was shown to inhibit MDA-MB-231 tumor growth and cause 
cell death as well as decrease extracellular VEGF, a marker of angiogenesis, in an 
ectopic mouse model of TNBC [209] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Molecular Mechanisms of Resveratrol Anti-cancer Activity. Adapted from [161]. 
The known molecular targets of resveratrol in various human cancers are shown 
grouped by type of target or physiological importance. 
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One mechanism of particular interest for resveratrol-induced apoptosis that has 
been generated through various works is through SIRT1 activation (Figure 5). 
Resveratrol is a well-known activator of the class III histone deacetylase protein, SIRT1. 
Recently, it was shown that resveratrol acts through the cAMP/PKA/AMPK pathway 
[210]. This pathway causes a phosphorylation event that dissociates SIRT1 from the 
negative protein regulator Deleted in Breast Cancer 1 (DBC1) [211]. Furthermore, SIRT1 
activation by resveratrol has been shown to directly deacetylate the survivin promoter, 
decreasing survivin transcription [212]. Survivin is an inhibitor of apoptosis protein that 
binds and inhibits activated pro-apoptosis caspase 3 and caspase 7. Decreased survivin 
protein levels allow activated caspase 3 and caspase 7 to induce apoptosis as well as 
paclitaxel-induced apoptosis [81]. This SIRT1/survivin mechanism provides one of many 
possible mechanisms of action of resveratrol alone and in combination with other 
treatments. 
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Figure 5. Hypothesized Mechanism of Resveratrol Induced Apoptosis. A) The survival 
pathway, which is hypothesized to be overactive in cancer cells, where DBC1 binds to 
SIRT1 and renders SIRT1 inactive allowing for the transcription of survivin. Survivin can 
then inhibit activated caspase 3 and 7 leading to cell survival. B) The hypothesized effect 
of resveratrol on the survival pathway where action on the cAMP/PKA/AMPK pathway 
causes SIRT1 and DBC1 dissociation. Free SIRT1 can then deacetylate the survivin 
promoter, which silences survivin expression allowing activated caspase 3 and 7 to 
cause apoptosis.  
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C. Resveratrol Combination Therapy 
 
There is evidence to suggest that resveratrol has the potential to cause both 
harmful and beneficial effects when combined with other drugs. Resveratrol is well 
known to inhibit a variety of CYPs, which could cause both harmful and beneficial drug 
interactions when taken in high doses [213]. One example of a potential positive CYP 
interaction is resveratrol was shown to inhibit CYP17A1 and was suggested to be useful 
in prostate cancer chemoprevention [214]. An example of a CYP interaction that could 
cause beneficial or harmful effects is the ability of resveratrol to inactivate CYP3A4, 
which has many substrates [215]. In addition, positive combination effects of resveratrol 
and irradiation has been seen in multiple cancer cell lines [216]. Resveratrol has also 
been shown to sensitize multiple cancer types to various chemotherapeutics and other 
agents [217, 218]. 
Resveratrol has been shown to have a positive combination effect with paclitaxel 
in Non-Hodgkin Lymphoma, multiple myeloma, non-small cell lung cancer, lung cancer 
and human oral epidermoid carcinoma cells [217]. However, the combination effect was 
attributed to different mechanisms including decreased Bcl-xL expression [219], an 
increase in p21 [220], a decrease of survivin [221], and decreases in P-gp and Bcl-2 
expression [222]. Conversely, it has also been shown that resveratrol can attenuate 
paclitaxel effects in neuroblastoma and bladder cancer cells in other studies [223-225]. 
These attenuation effects were also attributed to different mechanisms depending on the 
cell type such as decreased caspase-7 and caspase-3 expression, decreased PARP 
cleavage, Bcl-2 activity, decrease of reactive oxygen species, and effects on the cell 
cycle. Of particular interest, in one study resveratrol attenuated paclitaxel treatment in 
some breast cancer cells such as triple negatives, but not other breast cancer cells 
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[226]. These studies suggest resveratrol combination therapy may be cell type specific 
and clearly more research in the area is warranted. 
 
V. Preliminary Work and Study Objectives 
 
In a previous study from our laboratory, resveratrol was shown to have a biphasic 
effect on the growth of TNBC cells regardless of BRCA1 status [164]. An effect of 
promoting cell proliferation at low resveratrol concentrations and inhibiting growth at high 
resveratrol concentrations was observed by analysis of cell morphology, growth, survival 
and cell cycle. Interestingly, cells containing truncated, non-functional, mutant BRCA1 
were more sensitive to resveratrol than cells with wild-type BRCA1. The difference in 
resveratrol effect suggests a role of BRCA1 in resveratrol action and further suggests 
resveratrol may be particularly useful in the small subset of TNBCs with mutant BRCA1. 
Notably, this data showed for the first time that low micromolar concentrations of 
resveratrol could sensitize TNBC cells to paclitaxel (Figure 6). This positive combination 
effect was not different between cells with mutant and wild-type BRCA1. 
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Figure 6. Resveratrol Sensitizes HCC1937 Cells with Mutant or Wild-type BRAC1 to 
Paclitaxel. From [164]. Surviving fraction of HCC1937 cells with mutant or wild-type 
BRAC1 after a 24-hour simultaneous treatment of varying concentrations of paclitaxel 
and 10 μM resveratrol (n=3). Error bars denote standard deviation. Alone 10 μM 
resveratrol treatment had no effect on cell growth after 24 hours. 
 
 This work spurred our laboratory to formulate a hypothesis that resveratrol could 
be used in TNBC cells both sensitive and resistant to paclitaxel to improve response to 
paclitaxel. To study paclitaxel resistance in TNBCs a cellular model was developed that 
mimics the selection of resistant cells in a tumor, which can lead to the recurrence of a 
resistant tumor. The objectives of this study were to determine the effects of resveratrol 
as a single agent and the effects of resveratrol in combination with paclitaxel treatment 
in paclitaxel-sensitive and -resistant cells. Here data is presented that shows that 
resveratrol induced cell proliferation inhibition, senescence, and apoptosis in paclitaxel-
sensitive and -resistant TNBC cells. Importantly, the data show that resveratrol can be 
used in combination with paclitaxel to re-sensitize the resistant cells back to the parental 
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level and also to decrease the resistance of both resistant and parental cells below the 
original parental level. This effect of resveratrol on the paclitaxel sensitivity of these cells 
may be linked to the known ability of resveratrol to inhibit P-gp and CYP2C8 both of 
which were found in this study to be involved in the paclitaxel-resistance of our model. 
Overall, this work suggests that resveratrol can be used alone and in combination with 
paclitaxel in TNBCs regardless of the status of paclitaxel sensitivity. 
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CHAPTER 2: MATERIALS and METHODS 
 
I. CELL CULTURE 
 
A. Cell Culture and Reagents 
 
MDA-MB-231 cells (ATCC; Manassas, VA) were cultured in DMEM media 
(Corning cellgro; Corning, NY) with 10% Hyclone Cosmic Calf Serum (Thermo Fisher 
Scientific; Waltham, MA) at 37°C, 5% CO2 and 95% humidity. For regular cell sub-
culture, cells were washed with 1X Hank's Balanced Salt Solution (HBSS) and removed 
from the plate with 0.05% trypsin treatment for approximately 30 seconds. Resveratrol 
and paclitaxel (Sigma-Aldrich; St. Louis, MO) were dissolved in DMSO and further 
diluted with 1X HBSS. All treatments were conducted in the dark to preserve the stability 
of both light-sensitive drugs. 
 
B. Mycoplasma Testing 
 
Cells were periodically tested with the PCR-based VenorGeM Mycoplasma 
Detection Kit (Sigma-Aldrich; St. Louis, MO) per manufacturer’s instruction to ensure 
mycoplasma contamination was not present. 100 μL samples of media from cell culture 
were boiled at 95°C for 5 minutes, centrifuged and put on ice.  25 μL of PCR Mastermix 
(1 U Taq Polymerase, and 10% each of 10X reaction buffer, primer/nucleotide mix, and 
internal control) was mixed for each reaction. 23 μL of Mastermix was mixed with 2 μL of 
sample, positive control or DEPC-water as a negative control. Samples were run on an 
Mastercycler PCR machine (Eppendorf; Hamburg, Germany) with the following thermal 
cycle program: 1 cycle 94°C for 2 minutes; 39 cycles 94°C for 30 seconds, 55°C for 1 
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minute, 72°C for 30 seconds; cool down to 4°C. Samples were then mixed 5 μL to 1 μL 
of 6X loading buffer and run on an ethidium bromide agarose gel (1.5% agarose in 1X 
TBE, 0.02% ethidium bromide) for 20 minutes at 100V. The gel was then photographed 
using a GDS-8000 gel imaging system (UVP; Upland, CA). 
 
II. RESISTANT CELL LINE GENERATION 
 
To generate the paclitaxel-resistant line, an intermittent, stepwise method of 
treatment was used [227]. MDA-MB-231 cells were treated with the determined 24-hour 
IC30 of paclitaxel for 3-4 days. The drug was then removed for 3-4 days before treating 
again. This interval lasted for 2-4 weeks before the treatment was increased to the IC40. 
This process was repeated until the cells were growing successfully under IC60 treatment 
of paclitaxel. After these cells were obtained, they were no longer grown in the presence 
of paclitaxel. Single-cell derived clones were obtained by limiting dilution in which cells 
were serially diluted across a 96-well plate and single clones were expanded. Expansion 
was conducted by trypsinization of cells and plating cells onto progressively larger 
plates. 
 
III. CELL PROLIFERATION ASSAYS 
 
A. Methylene Blue Cell Proliferation Assay 
 
Cells were plated on 96 well plates at 2,000-10,000 cells per well, allowed to 
attach to the plate overnight, and treated with paclitaxel or resveratrol for 1-5 days. The 
media was aspirated, and cells were fixed in methanol for 15 minutes and then stained 
with 50 μL of 0.05% methylene blue stain (Ricca Chemical; Arlington, TX) for 10 minutes 
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[228]. The plates were washed with deionized water, dried and de-stained with 100 μL of 
0.5 M hydrochloric acid solution. The absorbance was then measured using a plate 
reader at 610 nm. For IC50 determinations, cells were treated with a serial dilution of 
paclitaxel or resveratrol. GraphPad Prism version 4.00 for Windows (GraphPad 
Software; San Diego, CA) was used to calculate IC50 values. 
 
B. Cell Count Proliferation Assay 
 
To measure cell proliferation, total cell counts were completed. In each well of 
12-well plates 15,000 cells were plated, allowed to attach to the plate overnight, and 
treated with resveratrol or DMSO vehicle control. Cells were collected by trypsinization 
and counted with a Z series Coulter Counter Cell and Particle Counter (Beckman 
Coulter, Inc.; Pasadena, CA) at 24, 48 and 72 hours post-treatment. 
 
C. Cell Survival Assays 
 
Two colony formation assays were performed. First, a plating efficiency assay 
was conducted as previously shown with modification [229]. Cells were plated at a 
density of 3x105 on T25 flasks, allowed to attach overnight, and treated with resveratrol 
or DMSO vehicle control for 3 days. Cells were then collected by trypsinization and 
plated on 6-well plates at 30 cells per well. Cells were allowed to grow for 17 days 
undisturbed. Second, a clonogenic cell survival assay was conducted as previously 
described with modifications [230]. Cells were plated in 6-well plates at 30 cells per well, 
allowed to attach to the plate overnight, and treated with resveratrol or DMSO vehicle 
control for 3 days. Treatment was then removed, and the cells were allowed to grow for 
17 days undisturbed. For both experiments, after the 17-day incubation, plates were 
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then washed with 1X HBSS and fixed with methanol for 15 minutes, stained with crystal 
violet for 1 hour and washed with deionized water. Colonies consisting of 50 cells or 
more were then counted and scored. 
 
D. Checkerboard Drug Combination Assay 
 
Combination assays were completed using a checkerboard method such that 
cells plated onto 96-well plates at a density of 4,000 cells per well were treated for 5 
days with a serial dilution of paclitaxel across the plate horizontally and a dilution of 
resveratrol across the plate vertically. The plates were processed using the methylene 
blue cell proliferation method as described above. It is important for the data analysis 
that the serial dilution for both drugs is the same; for example, a one to two dilution was 
used for both drugs. This provides constant drug ratios across the diagonal of the plate. 
The amount of resveratrol used was the same for both cell lines (2.5-40 μM). The 
amount of paclitaxel used was different for both cell lines. An amount of paclitaxel was 
chosen to provide a full paclitaxel curve for each cell line. The parental MDA-MB-231 
cells, therefore, were treated with less paclitaxel (0.244-31.25 nM) than the resistant 
MDA-MB-231/PacR cells (3.906-500 nM). It is important to note that differences in drug 
ratio were due to a change in paclitaxel concentration rather than resveratrol ratio. 
However, as it is the drug ratios that are compared, paclitaxel concentrations used for 
the two cell lines were chosen to provide four drug ratios in common between the two 
cell lines. This allowed for direct comparison of effects of these drug ratios between the 
two cell lines. The method can be used to determine if a drug combination is 
antagonistic, additive, or synergistic by graphing the data as an isobologram with the 
axes representing the concentration of one drug versus the other. For example, the IC50 
value of resveratrol alone is plotted on the y-axis and IC50 value of paclitaxel alone on 
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the x-axis; these two points are connected to provide the line of additivity. Each drug 
ratio is represented on the graph as a single point based on the IC50 value for both drugs 
at this ratio. Any point that falls on the line of additivity denotes an additive effect, below 
the line denotes synergistic effect, and above the line denotes an antagonistic effect of 
the drug combination. Antagonism denotes a reduction of drug efficacy, an additive 
effect suggests an efficacy that is equal to the effects of the two drugs alone added 
together, and synergy denotes an improvement of effect of both drugs compared to each 
drug alone. The data were analyzed by determining the IC50 value for the constant drug 
ratio curves using the Chou Talalay method [231, 232]. 
 
E. Inhibitor Assay 
 
For the P-gp and CYP2C8 inhibitor assays, the methylene blue method was used 
as described above. Cells were treated for 5 days with a serial dilution of paclitaxel 
either alone or in combination with 1 μM verapamil (Sigma-Aldrich; St. Louis, MO), 25 
μM trimethoprim (Sigma-Aldrich; St. Louis, MO) or both. GraphPad Prism version 4.00 
for Windows (GraphPad Software; San Diego, CA) was used to calculate IC50 values. 
IC50 values from different trials were averaged and compared using Microsoft Excel 2011 
version 14.4.1. 
 
IV. MOLECULAR TECHNIQUES 
 
A. Cell Cycle Analysis 
 
To analyze the cells’ cycle phases following resveratrol treatment, cells were 
plated at a density of 1x106 in T75 flasks, allowed to attach to the plate overnight, and 
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treated with resveratrol or DMSO vehicle control for 48 hours. All cells in the media and 
those attached to the plate were collected using trypsinization and centrifugation. Cells 
were resuspended in 1X HBSS to wash the pellet and cells were counted. After 
centrifugation and removal of the 1X HBSS cells were resuspended in 0.5 mL 1X PBS 
and kept on ice. Cells were fixed and permeablized by adding 4.5 mL of 70% ethanol 
dropwise while vortexing. Cells were then stored at -20°C. To stain for flow cytometry 
analysis, samples were centrifuged for 5 minutes and the supernatant was decanted. 
Cells were gently washed with 1X PBS and centrifuged, and the supernatant was 
decanted. Cells were resuspended in 100 uL binding buffer (0.1% TritonX-100 in PBS, 
0.0002% DNase-free RNase A) and then stained with 5 μL propidium iodide (PI) staining 
solution (BD Biosciences; Franklin Lakes, NJ). An unstained control was prepared for 
each cell line with cells not treated with resveratrol; these controls are important for 
setting up flow cytometry conditions. Cells were gently vortexed and incubated at room 
temperature for 15 minutes in the dark. Cells were then diluted with 400 μL binding 
buffer. Samples were put through a 35 μm cell strainer and vortexed before mounting 
sample tube to flow cytometer. Fluorescence was measured using a LSRII 561 nM laser 
flow cytometer (BD Biosciences; San Jose, CA), and data was analyzed with FlowJo 
(TreeStar; Ashland, OR). 
 
B. Senescence Staining 
 
Cells were plated at 15,000 cells per well onto 24-well plates, allowed to attach to 
the plate overnight, treated with resveratrol or DMSO vehicle control for 3 days, and then 
stained using the Senescence Detection Kit (EMD Millipore; Billerica, MA) per 
manufacturer’s instructions with modifications. Culture media was aspirated, and the 
plates were washed with 1X PBS. Cells were then fixed with 200 μL of Fixative Solution 
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at room temperature for 10 minutes. Cells were washed twice with 1X PBS and the 
stained at 37 °C overnight with 200 μL Staining Solution. The activity of β-galactosidase 
is a hallmark of senescent cells. The staining solution of this kit contains X-gal, which is 
cleaved by β-galactosidase to produce a blue dye. Therefore, blue cell staining denotes 
a positive result or senescent cell, and no staining denotes a negative result. Positive 
and negative cells were counted and scored from images provided using a phase-
contract microscope at 20X. The experiment was conducted three separate times, and 
three representative fields for each treatment from each experiment were counted and 
scored. 
 
C. Immunofluorescence 
 
Cells were plated on 8-well glass chamber slides at 40,000 cells per well and 
were allowed to attach overnight. Media was removed and wells were washed with 1X 
HBSS. Cells were fixed to the plate with 100% methanol for 10 minutes and washed 
three times with 1X PBS for 5 minutes. The cells were then permeabilized with 0.2% 
Triton-X100 in 1X PBS for 10 minutes. Cells were washed again as before. The chamber 
was then removed and the cells were mounted to the slide with Vectashield Mounting 
Medium with DAPI (Vector Laboratories; Burlingame, CA). A coverslip was then sealed 
to the slide. Slides were then visualized with a fluorescence microscope. 
 
D. Annexin V Apoptosis Flow Cytometry 
 
For apoptosis analyses, 1,000,000 cells were plated in T75 flasks, allowed to 
attach to the plate overnight, and treated with resveratrol or DMSO vehicle control for 3 
or 5 days. All cells in the media and attached to the plate were collected using 
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trypsinization and centrifugation. Cells were stained with FITC-conjugated Annexin V 
and PI using the FITC Annexin V Apoptosis Detection Kit I (BD Biosciences; Franklin 
Lakes, NJ) according to manufacturer’s instructions. Collected cells were washed twice 
with 1X HBSS, and 1,000,000 cells were resuspended in 100 μL of 1X Binding Buffer. 
To stain the cells, 5 μL of FITC Annexin V and 5 μL of PI were added to the samples. An 
unstained, FITC Annexin V only, and PI only control were prepared for each cell line with 
cells not treated with resveratrol; these controls are important for setting up flow 
cytometry conditions. Samples were then gently vortexed and incubated for 15 minutes 
at room temperature in the dark. Samples were diluted with 400 μL of 1X Binding Buffer, 
put through a 35 μm cell strainer, and vortexed before mounting sample tube to flow 
cytometer. Fluorescence was measured using a LSRII 561 nM laser flow cytometer (BD 
Biosciences; San Jose, CA), and data was analyzed with FlowJo (TreeStar; Ashland, 
OR). 
 
E. Immunoblotting 
 
Cells were plated on T75 flasks, allowed to attach overnight, and treated with 
resveratrol or DMSO vehicle control for 2, 3 or 5 days. Cells were collected by 
trypsinization, washed with 1X HBSS, pelleted, and snap frozen in an -80°C freezer. 
Pellets were resuspended in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 37 mM β 
glycerol phosphate, 47 mM NaF, 1% NP-40, 0.1% SDS, 0.5% Na deoxycholate, 10% 
glycerol) supplemented with protease inhibitor cocktail (Hoffmann-La Roche; 
Switzerland) and phosphatase inhibitor cocktail (Thermo Fisher Scientific; Waltham, MA) 
and were lysed by sonication for 10 seconds at 30 amperes. The protein content of the 
samples was estimated using a Pierce BCA Protein Assay Kit. A standard curve of 
protein concentration was created with lysis buffer, water and 2mg/mL BSA. Protein 
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samples were diluted 1:10 and 10 μL of standards and samples were added to a 96-well 
plate.  200 μL of a mix of 50 parts Reagent A to 1 part Reagent B was added to each 
well and mixed well. The plate was incubated at 37°C for 30 minutes. The plate was then 
cooled to room temperature and read on a plate reader at 562 nm. The standard curve 
was then used to estimate protein concentration of prepared samples. Ten or 25 μg of 
protein was mixed 1:1 with 2X Laemmli Buffer (4% SDS, 20% glycerol, 10% 2-
mercaptoethanol, 0.008% bromphenol blue and 0.125 M Tris HCl pH 6.8) and boiled at 
95°C for 5 minutes. Samples were run on 6, 10 or 12% polyacrylamide gels using 1X 
Tris/glycine SDS (0.25 M Tris base, 0.96 M glycine, 0.5% SDS, pH 8.3) running buffer. 
PVDF membranes (Pall Corporation; Port Washington, NY) and 1X Transfer Buffer (0.25 
M Tris base, 0.192 M glycine, 20% methanol, pH 8.3) were used for overnight (13V) or 
2-hour (80V) transfer. Blotting was conducted using 5% milk in 0.1% Tween PBST or 5% 
BSA in 0.1% Tween TBST for phosphorylated proteins. All blots were incubated with 
primary antibody (1:1000-1:5000) at 4°C overnight and secondary antibody (1:5000-
1:10,000) for 0.5-1 hour at room temperature with gentle agitation. Primary antibodies 
SIRT1 (Active Motif; Carlsbad, CA), DBC1, Survivin, Caspase 7, Caspase 3, AMPK, and 
P-AMPK (Cell Signaling; Danvers, MA) and secondary antibodies anti-mouse and anti-
rabbit (Thermo Fisher Scientific; Waltham, MA) were used according to manufacturer’s 
suggestion. Pierce ECL Western Blotting Reagent (Thermo Fisher Scientific; Waltham, 
MA) was used to visualize bands on X-ray film per manufacturer’s instructions. An X-ray 
film developer was used to develop the film, and ImageJ was used for densitometry 
quantification. 
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F. siRNA Knockdown 
 
Caspase 7 and Non-Targeting Dharmacon ON-TARGETplus SMARTpool siRNA 
constructs were used with Dharmacon lipofection transfection reagent (Thermo Fisher 
Scientific; Waltham, MA) according to manufacturer’s instructions. Dharmacon ON-
TARGETplus SMARTpool siRNAs, which contain a pool of 3-4 siRNAs, were 
reconstituted with 1X siRNA buffer (60 nM KCl, 6 mM HEPES-pH 7.5, and 0.2 mM 
MgCl2) for a final stock concentration of 5 μM. The siRNA and siRNA buffer solution was 
mixed gently by pipetting without introduction of bubbles and incubated for 30 minutes at 
room temperature with gentle agitation. Aliquotes of siRNA were stored at -20°C. Cells 
were plated on 6-well plates at 200,000 cells per well and allowed to attach overnight. 
Cells were transfected with 25 nM siRNA and 0.1% transfection reagent. Transfection 
media was prepared by gently mixing siRNA and transfection reagent individually with 
serum-free media and incubating for 5 minutes at room temperature. The two mixtures 
were then gently mixed together and incubated for 20 minutes at room temperature. 
Complete media was added to the mixture and cells were treated with 1 mL of 
transfection media for 96 hours. The transfection media was then removed and the cells 
were then treated with resveratrol or DMSO vehicle control for 48 hours before the cells 
were collected and analyzed by immunoblotting as described above. 
 
G. Co-immunoprecipitation 
 
Cells were plated on 10 cm dishes and left to attach overnight. The cells were 
then treated for 2 hours with resveratrol or DMSO vehicle control and collected by 
scraping in 1 mL of 1X PBS. The cells were pelleted in a centrifuged at 10,000 rpm for 5 
minutes and PBS was aspirated. The pellets were resuspended in co-
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immunoprecipitation lysis buffer (25mM Tris, pH 8.0, 150mM NaCl, 0.5 mM EDTA, 0.5 
mM EGTA, 1% NP-40) supplemented with protease inhibitor cocktail (Hoffmann-La 
Roche; Switzerland). The samples were lysed on ice for 30 minutes with vortexing every 
10 minutes. The samples were then spun down as before and the supernatant was put 
into a new tube. The protein concentration was then determined as described in the 
“Immunoblotting” section. Along with untreated and treatment samples, a “lysate and 
bead only” control was prepared with untreated cells as a background control. 1500 μg 
of protein was added to a new sample tube for each sample. 2.5 μg of SIRT1 antibody 
was added to all but the “lysate and bead only” control. The total volume of each sample 
was brought up to 1 mL with lysis buffer, and the samples were incubated at 4°C with 
gentle agitation overnight. Protein A/G PLUS-Agarose Immunoprecipitation Reagent 
(Santa Cruz Biotechnology; Santa Cruz, CA) was used to collect the SIRT1-SIRT1 
Antibody complex. A slurry of A/G beads in PBS was made to provide enough beads to 
coat the bottom of an Eppendorf tube by adding 37.5 μL of bead slurry. This 37.5 μL of 
bead slurry was then added to each sample and incubated for 2 hours at 4°C with gentle 
agitation. To collect beads, samples were spun down for 30 seconds at 8,000 rpm and 
supernatant was aspirated. Beads were rinsed 3 times with 1 mL cold 1X PBS on ice 
and gentle agitation for 10 minutes. After final rinse, 10 μL of cold PBS and 10 uL of 2X 
Laemmli Buffer was added to the beads. Samples were boiled on a heat block for 7 
minutes at 95°C with vortexing three times during boiling. Samples were then spun down 
and the supernatant was loaded onto a polyacrylamide gel to be analyzed by 
Immunoblotting as was described above. 
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H. RNA Extraction 
 
PCR based assays were used to explore possible mechanisms of resistance, 
which required RNA extracts from cell samples. Untreated cells were collected by 
trypsinization, washed, pelleted and snap frozen in an -80°C freezer. For all PCR based 
assays, RNase Away Decontamination Solution (Thermo Fisher Scientific; Waltham, 
MA) was used to keep the working area free of RNase contamination. RNA extraction 
was performed according to manufacturer’s instructions using the RNeasy Mini Kit 
(Qiagen; Holland). Cell pellets were resuspended in 350 μL of Buffer RLT and the cell 
lysates were homogenized by passing the lysates through a blunt 20-gauge needle 5 
times. Before addition to the column, 350 μL of 70% ethanol was then added to the 
lysates and mixed well. The lysates were then transferred to RNeasy Mini Kit spin 
columns placed in a 2 mL collection tube and centrifuged for 15 seconds at 10,000 rpm 
to transfer sample to the spin column membrane. Flow-through was discarded and 700 
μL Buffer RW1 was added to the columns to wash the membrane. Samples were 
centrifuged again and flow-through was discarded. After adding 500 μL Buffer RPE to 
the columns to further wash the membrane, the columns were spun and flow-through 
discarded again. Another 500 μL Buffer RPE was added to the columns, and the sample 
was centrifuged for 2 minutes at 10,000 rpm. The spin columns were then placed in new 
2 mL collection tubes and centrifuged at 13,200 rpm for 1 minute. Finally, the spin 
columns were placed in new 1.5 mL collection tubes, 40 μL of RNase-free water was 
added directly to the spin column membranes, and the samples were spun at 10,000 
rpm for 1 minute to elute RNA from the membrane.  Another 40 μL was added to the 
column and the spin repeated to ensure elution of all RNA. RNA concentration and purity 
of the eluate was determined using a NanoDrop spectrophotometer. 
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I. cDNA Synthesis 
 
The RT2 First Strand Kit (Qiagen SABiosciences; Holland) was used to 
synthesize cDNA from RNA samples for both the RT2 Profiler PCR Array and the RT2 
qPCR Primer Assay according to manufacturer’s instructions. Genomic DNA was 
eliminated from the RNA samples by mixing 0.5 μg of RNA with 2 uL of Buffer GE and 
RNase-free water to 10 μL total volume. This genomic DNA elimination mix was 
incubated at 42°C for 5 minutes and then placed immediately on ice for at least 1 
minute. Reverse-transcription mix (4 μL 5X Buffer BC3, 1 μL Control P2, 2 μL RE3 
Reverse Transcriptase Mix, and 3 μL RNase-free water) was prepared for each reaction 
and 10 μL was added to each tube containing 10 μL genomic DNA elimination mix and 
mixed gently. Samples were incubated at 42°C for exactly 15 minutes. The reaction was 
then immediately stopped by incubating at 95°C for 5 minutes. Finally, 91 μL RNase-free 
water was mixed gently into each sample, and the samples were placed on ice or stored 
at -20°C. 
 
J. RT2 Profiler PCR Array 
 
The Human Cancer Drug Resistance RT2 Profiler PCR Array (Qiagen 
SABiosciences; Holland) was used according to manufacturer’s instructions. The array 
was performed a total of three times from the same cDNA sample for each cell line. The 
PCR components (50% 2X RT2 SYBR Green Mastermix, 3.8% cDNA and 46.2% 
RNase-free water) were mixed for a 96-well array for each cell line at room temperature 
and 25 μL of the mixture was added to each well of the array using a 8-channel pipettor 
changing pipet tips following each pipetting step to avoid cross-contamination. The array 
plate was tightly sealed with optical thin-wall 8-cap strips. The plates were centrifuged 
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for 1 minute at 10,000 rpm at room temperature to remove bubbles and were placed on 
ice until ready to run real-time PCR. Real-time PCR was performed on an ABI 7500 
machine with the following program: 1 cycle 95°C for 10 minutes; 40 cycles 95°C for 15 
seconds, 60°C for 1 minute (perform fluorescence data collection); dissociation curve 
analysis. The 7500 Software version 2.0.6 was used to determine CT values and the 
SABiosciences PCR Array Data Analysis Template Excel was used to analyze the data. 
 
K. RT2 qPCR Primer Assay 
 
Primers for ABCB1, CYP2C8, and actin (Qiagen SABiosciences; Holland) were 
used in combination with the corresponding RT2 Primer Assay (Qiagen SABiosciences; 
Holland) reagents and used according to manufacturer’s instructions. Three biological 
replicates were run in triplicate. The PCR components (50% RT2 SYBR Green 
Mastermix, 4% cDNA, 4% 10 μM RT2 qPCR Primer, 42% RNase-free water) were mixed 
for a total volume of 25 μL per reaction and were added to 96-well PCR plates. The 
plates were sealed with adhesive film, centrifuged for 1 minute at 10,000 rpm at room 
temperature to remove bubbles, and placed on ice until ready to run real-time PCR. 
Real-time PCR was performed on an ABI 7500 machine with the same program used for 
the PCR Array. The 7500 Software version 2.0.6 was used to determine CT values and 
the 2^(-ΔΔCT) method [233] was used to determine fold changes of gene expression 
between the parental, MDA-MB-231 cells, and the resistant MDA-MB-231/PacR and 
MDA-MB-231/PacR-Hi cells. P-values and standard deviations for PCR Array and real-
time RT-PCR validation were calculated based on a Student’s t-test of the replicate 2^(-
ΔCT) values for each gene in the control group and treatment groups as suggested by 
the manufacturer. 
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V. STATISTICS 
 
Student’s T-Test, two- and one-way ANOVA with Bonferroni correction were 
used to determine p-values where appropriate using GraphPad Prism4 software where 
p<0.05 was considered statistically significant.
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CHAPTER 3: RESULTS 
 
I. PACLITAXEL-RESISTANT CELLULAR MODEL GENERATION 
 
To provide a cellular model of acquired paclitaxel resistance in MDA-MB-231 
breast cancer cells, a paclitaxel resistant cell line was developed by an intermittent, 
stepwise treatment with paclitaxel (Figure 7). A continuous, stepwise method was also 
attempted but the resulting population did not develop as much resistance, based on 
IC50 analysis at a 24-hour paclitaxel treatment time, or grow as well as the population 
derived from the intermittent, stepwise method. Therefore, we continued experiments 
with the population derived by intermittent, stepwise paclitaxel treatment. The cells were 
no longer cultured in the presence of paclitaxel after the final population was acquired. 
The limiting dilution cloning method was used to provide a more homogeneous 
population and yielded 29 clones that could be successfully established as resistant cell 
lines. These cells were originally assessed with a 24-hour paclitaxel treatment. The cells 
did not lose paclitaxel-resistance even after up to 20 passages post-cloning. 
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Figure 7. Schematic of Drug Resistant Cell Line Generation. Cells were treated with a 
stepwise increase of the 24-hour paclitaxel IC50 calculated from the methylene blue 
proliferation assay. Between each stepwise increase was a 2 to 4 week period of 
intermittent treatment. This intermittent treatment was conducted with repeatedly treating 
the cells with paclitaxel for 3 to 4 days, removing the drug, and allowing the cells to 
recover for 3 to 4 days. The resulting population was then cloned using the limiting 
dilution method. 
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II. RESVERATROL INDUCES CELL PROLIFERATION INHIBTION, SENESCENCE, 
AND APOPTOSIS 
 
A. Resveratrol Inhibits Cell Proliferation 
 
To determine the effects of resveratrol in these paclitaxel-sensitive and -resistant 
TNBC cells, the effects of resveratrol on cell proliferation of parental MDA-MB-231 and 
highly resistant MDA-MB-231/PacR cells were tested. To determine any correlation 
between paclitaxel resistance and resveratrol sensitivity, the 24-hour paclitaxel IC50 and 
72-hour resveratrol IC50 were graphed against each other and a ‘line of best fit’ analysis 
was performed in Excel (Figure 8). The ‘line of best fit’ analysis resulted in a correlation 
coefficient of 0.046, suggesting no correlation. Due to the fact that a 24-hour time point 
of resveratrol does not provide a full IC50 curve, a longer time point of 5 days was used 
for further experiments. Of the 29 clones, the 12-fold increased resistance clone, MDA-
MB-231/PacR, was selected for further study. The 5-day IC50 value of the parental MDA-
MB-231cells was 5.1 ± 2.3 nM compared to 61.5 ± 9.5 nM for the MDA-MB-231/PacR 
cells. In addition, another clone was chosen for use in resistance mechanism 
experiments to provide comparison and validate the importance of the mechanism in 
more than one clone. The clone chosen, MDA-MB-231/PacR-Hi, was observed to have 
a 5-day IC50 value of 117.5 ± 42.7 nM. Though the population doubling of the MDA-MB-
231/PacR cells was increased to 52 hours compared to the MDA-MB-231 cells at 35 
hours, 10 and 100 μM resveratrol significantly inhibited the ability of both cell populations 
to proliferate (Figure 9). Treatment with 100 μM resveratrol in a colony formation and 
clonogenic cell survival assay completely inhibited colony formation in both cell lines, 
indicating that resveratrol inhibited the ability of a single cell to proliferate (Figure 10A-B). 
In both assays, 10 μM resveratrol treatment decreased colony formation, but the 
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decrease was only statistically significant for the surviving fraction in the MDA-MB-
231/PacR cells. The difference in population doubling time between the two cell lines is 
illustrated by the larger colony size seen in the MDA-MB-231/PacR cells (Figure 10C).
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Figure 8. Paclitaxel Resistance is Not Correlated to Resveratrol Sensitivity. Each 
paclitaxel-resistant clone generated graphed by 24-hour paclitaxel IC50 versus 72-hour 
resveratrol IC50. Line represents the line of best fit, and the R2 is the correlation 
coefficient of the line of best fit.
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Figure 9. Resveratrol Inhibits Cell Proliferation. A) Total cell counts from plates seeded 
with 1.5x104 cells 24-72 hours post resveratrol treatment of MDA-MB-231 and B) MDA-
MB-231/PacR. cells (n=3) (UT=untreated; *p<0.05; **p<0.01; ***p<0.001; *p-values 
compare treatment to DMSO control).
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Figure 10. Resveratrol Inhibits Colony Formation. A) Plating efficiency and B) Surviving 
fraction of cells plated at low density after 72 hours of resveratrol treatment followed by a 
17-day incubation without drug (n=3) and C) representative pictures of untreated 
colonies from clonogenic, colony formation assay. Error bars signify standard deviation 
(UT=untreated; *p<0.05; **p<0.01; ***p<0.001; *p-values compare resveratrol treatment 
to DMSO control).
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B. Resveratrol Induces Sub-G1 Phase Accumulation 
 
Due to the inhibition of cell proliferation observed in both cell lines by resveratrol, 
we next analyzed the effect of resveratrol on cell cycle profiles in parental MDA-MB-231 
and MDA-MB-231/PacR cells. We chose a 48-hour time point based on the cell 
proliferation data which indicates a difference between vehicle treated and resveratrol 
treated is just becoming evident. In addition, a higher concentration, 300 μM, of 
resveratrol was added to evaluate the effects of resveratrol at concentrations previously 
used in anti-cancer studies [234, 235] and shown to accumulate in tissues [178]. At 48 
hours, neither 100 nor 300 μM resveratrol treatment in either cell line caused any 
accumulation in G1, G2/M or S phase compared to vehicle control (Figure 11). There 
was a decrease of cells in G1 phase after 300 μM resveratrol treatment in both cell lines. 
This population decreased from 46% to 4% in MDA-MB-231 cells and 41% to 8% in 
MDA-MB-231/PacR cells. Importantly, there was accumulation in Sub-G1 phase in both 
cell lines, which suggests apoptosis. In the MDA-MB-231 cell line, the Sub-G1 phase 
increased from 3% in the untreated and DMSO treated to 18% and 49% in the 100 and 
300 μM treated cells, respectively. In the MDA-MB-231/PacR cell line, the Sub-G1 phase 
increased from 8% in the untreated and DMSO treated to 23% and 34% in the 100 and 
300 μM treated cells, respectively. In addition, in both cell lines 300 μM resveratrol 
caused accumulation of a peak with higher DNA content than G2/M phase, but not 
enough to denote cell aggregation or mitotic catastrophe. The population increased from 
10% to 24% in the MDA-MB-231 and 9% to 26% in the MDA-MB-231/PacR cells. Due to 
the presence of micronuclei in both cell populations (Figure 12), as well as literature 
suggesting micronucleated calls can collect between G1 and G2 phase and after G2/M 
phase [236], we hypothesize this peak represents a population of micronucleated cells.
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Resveratrol Induces Sub-G1 Accumulation. Cell cycle analysis measureing PI 
staining with flow cytometry showing percent of cells in each phase after 48 hours of 
resveratrol treatment in A) MDA-MB-231 and B) MDA-MB-231/PacR cells (n=4). 
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Figure 12. Micronuclei are Present in MDA-MB-231 & MDA-MB-231/PacR Cells. A) 
DAPI staining of the nuclei (40X magnification) of MDA-MB-231 cells and B) MDA-MB-
231/PacR cells. White arrows indicate micronuclei.
MDA-MB-231 A 
B MDA-MB-231/PacR 
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C. Resveratrol Induces Senescence 
 
Because we observed inhibition of cell proliferation without a prominent cell cycle 
arrest with 10 or 100 μM resveratrol treatment, we hypothesized resveratrol treatment 
was causing senescence in some of the cells. Due to the greatest cell proliferation 
difference occurring at 3 days, we used this treatment time to look for senescent cells. 
After 100 μM resveratrol treatment, 37% of MDA-MB-231 and 38% of MDA-MB-
231/PacR cells were observed to be senescent by positive β-galactosidase staining 
(Figure 13). A treatment of 10 μM resveratrol caused a slight increase in senescence in 
both cell lines, but this increase was only statistically significant in the MDA-MB-
231/PacR cells. In these pictures, the hallmark cellular morphology of senescent cells, 
an enlarged and flattened appearance [237], can also be seen in the blue stained, β-
galactosidase positive cells.
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Figure 13. Resveratrol Induces Senescence. A) Representative fields of β-Galactosidase 
senescence staining after 48 hours of resveratrol treatment. White arrows point to blue 
stained, positive cells. Scale bar represents 200 μm. B) Quanitifcation of percent positive 
β-Galactosidase cells from three representative fields (n=3). Error bars signify standard 
deviation (*p<0.05; **p<0.01; ***p<0.001; *p-values compare treatment to DMSO 
control).
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D. Resveratrol Induces Apoptosis 
 
To ensure that the accumulated sub-G1 phase cells were apoptotic, Annexin V 
flow cytometry was conducted. This method differentiates between early apoptosis and 
late apoptosis/necrosis. After 3 days of resveratrol treatment, apoptosis was observed in 
both cell lines at 300 μM and in MDA-MB-231 cells at 100 μM resveratrol as well (Figure 
14A). In MDA-MB-231 cells treated with 300 μM resveratrol, 59% late apoptosis/necrosis 
and 37% early apoptosis was observed for a total of 96% of cells undergoing apoptosis. 
In MDA-MB-231/PacR cells, 71% late apoptosis/necrosis and 18% early apoptosis was 
observed for a total of 89% of cells undergoing apoptosis. At this 3-day time point, 100 
μM of resveratrol caused a statistically significant increase only in MDA-MB-231 cells 
when early and late apoptosis were added together (p<0.001). After 5 days of 
resveratrol treatment, both 100 and 300 μM treatment caused early and late apoptosis in 
both cell lines (Figure 14B). 300 μM resveratrol caused a total 96% of the cells to 
undergo apoptosis in both cell lines with 52% and 44% of MDA-MB-231 cells and 58% 
and 38% of MDA-MB-231/PacR cells being late and early apoptotic, respectively. When 
treated with 100μM resveratrol for 5 days, the percentage of total apoptotic cells was 
64% of MDA-MB-231 cells (p < 0.001), made up of 46% late and 18% early apoptotic, 
and 53% of MDA-MB-231/PacR cells (p < 0.01), made up of 37% late and 16% early 
apoptotic cells.  
To determine the importance of caspase 3 and caspase 7 in resveratrol-induced 
apoptosis, immunoblotting analysis was utilized. Procaspase, the inactive form, and 
cleaved caspase, the active form, were both measured. Caspase activation is a late 
apoptosis event. Due to the early and late apoptosis seen at 3 and 5 days we used 
these as well as a 48-hour time point to obtain a broad idea of caspase activity after 
resveratrol treatment. After 48 hours of 300 μM resveratrol treatment, procaspase 7 was 
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significantly decreased and cleaved caspase 7 was significantly increased for both cell 
lines (Figure 15). Slight activation of caspase 7 was seen with 100 μM of resveratrol 
treatment at this 48-hour time point though it was not statistically significant. After 3 and 
5 days of resveratrol treatment, the activation of caspase 7 decreases in the 300 μM 
treatment, which is likely due to activated caspases being degraded after activation. In 
contrast, Caspase 7 activates in the 100 μM treatment group for both cell lines at 3 and 
5 days (Figure 16). In addition, at 48 hours there was a decrease of procaspase 3 and 
slight but significant activation of caspase 3 with 300 μM treatment (Figure 17). 
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Figure 14. Resveratrol Induces Apoptosis. A) Percent of cells undergoing early (gray) 
and late (black) apoptosis measured by Annexin V/PI flow cytometry after 3 days and B) 
5 days of resveratrol treatment (n=3). Error bars signify standard deviation (*p<0.05; 
**p<0.01; ***p<0.001; *p-values compare treatment to respective DMSO control). 
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Figure 15. Caspase 7 Activation Occurs at 48 Hours with 300 μM Resveratrol Treatment. 
A) Representative immunoblot from three independent experiments of caspase 7 at 48 
hours after resveratrol treatment. B) Densitometry quantification normalized to actin of 
procaspase 7 and C) cleaved caspase 7 (n=3). Error bars signify standard deviation 
(*p<0.05; **p<0.01; ***p<0.001; *p-values compare treatment to respective DMSO 
control).
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Figure 16. Caspase 7 Activation Occurs at 3 & 5 Days with 100 μM Resveratrol 
Treatment. Densitometry quantification normalized to actin of A) procaspase 7 and B) 
cleaved caspase 7 at 3 days and C) procaspase 7 and D) cleaved caspase 7 at 5 days 
(n=3). Error bars signify standard deviation (*p<0.05; **p<0.01; ***p<0.001; *p-values 
compare treatment to respective DMSO control).
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Figure 17. Caspase 3 Activation Occurs Before 48 Hours with 300 μM Resveratrol 
Treatment. Densitometry quantification normalized to actin of A) procaspase 3 and B) 
cleaved caspase 3 at 48 Hours and C) procaspase 3 at 3 days (n=3). Error bars signify 
standard deviation (*p<0.05; **p<0.01; ***p<0.001; *p-values compare treatment to 
respective DMSO control; †p-values compare untreated and DMSO control).
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E. Resveratrol Decreases Survivin Protein Expression at High Concentration 
 
To explore possible mechanisms of resveratrol action, survivin and SIRT1 
pathways were examined as these have been shown to be important in other cancer 
cells [212]. Complete inhibition of survivin protein expression was achieved with 300 μM 
resveratrol at 48 hours and persisted for at least 5 days (Figure 18). However, while 
apoptosis occurred at 3 and 5 days of 100 μM treatment, there was no significant 
difference in survivin protein levels, suggesting survivin may not be critical in resveratrol-
induced apoptosis in these cells at this lower concentration (Figure 18C-D). 
Furthermore, the decrease of survivin with 300 μM resveratrol may not be caused by 
caspase 7 cleavage activity as neither 40% caspase 7 knockdown in MDA-MB-231 cells 
nor 70% in MDA-MB-231/PacR cells resulted in any recovery of survivin levels (Figure 
19). This result was further supported by the activation of caspase 7 in both cell lines 
treated with 100 μM resveratrol (Figure 16C-D) with no resulting decrease in survivin 
expression (Figure 19B). Resveratrol showed no effect on the expression of SIRT1 or 
the protein regulator of SIRT1, DBC1, in these cell lines (Figure 20). To determine 
activation of AMPK after 2 hours of resveratrol treatment, levels of phosphorylation on 
threonine 172 were measured by immunoblotting as this phosphorylation highly 
correlates with kinase activity [238]. Although 300 μM resveratrol did activate AMPK 
(Figure 21), which has been shown to cause dissociation of SIRT1 and DBC1 [210], co-
immunoprecipitation studies showed little to no association of SIRT1 and DBC1 in these 
cells (Figure 22). In MDA-MB-231 cells there was little to no binding in any of the three 
separate co-immunoprecipitation experiments conducted. The binding of SIRT1 and 
DBC1 in the MDA-MB-231/PacR cells was more pronounced, but very erratic. Although 
binding was seen in the untreated DMSO (100) and 100 μM resveratrol group in the first 
trial, the second trial only week binding in untreated and DMSO (300). In the final trial, 
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association was seen between SIRT1 and DBC1 in only the DMSO (100), 100 μM and 
300 μM resveratrol groups. To ensure that our co-immunoprecipitation protocol was not 
the cause of the erratic binding, a breast cancer cell line, the MDA-MB-468 cells, that 
has been shown to have SIRT1 and DBC1 binding was used (Figure 23). The three 
independent experiments with the MDA-MB-468 cells demonstrated more consistent 
association between SIRT1 and DBC1. These data provide a possible mechanism for 
both 100 and 300 μM resveratrol action that requires further investigation (Figure 24).
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Figure 18. Resveratrol Inhibits Survivin Expression at High Concentration. A) 
Representative immunoblot of survivin at 48 hours after resveratrol treatment B) 
Densitometry quantification normalized to actin of survivin after 48 hours C) 3 days and 
D) 5 days (n=3). Error bars signify standard deviation (*p<0.05; **p<0.01; ***p<0.001; *p-
values compare treatment to respective DMSO control).
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Figure 19. Caspase 7 Knockdown Does Not Affect Resveratrol-Induced Survivin 
Decrease. A) Percent knockdown achieved in three independent experiments using a 
pool of 4 siRNAs targeting Caspase 7 at 48 hours post a 96 hour transfection (n=3). B) 
Densitometry quantification normalized to actin of survivin expression following 96 hour 
siRNA transfection and subsequent 48-hour resveratrol treatment (n=3). Error bars 
signify standard deviation (*p<0.05; **p<0.01; ***p<0.001; *p-values compare treatment 
to respective DMSO control).
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Figure 20. Resveratrol Does Not Affect Protein Expression of DBC1 & SIRT1. A) 
Representative immunoblots of SIRT1 and DBC1 after 2 hours of resveratrol treatment. 
B) Densitometry quantitation normalized to actin of DBC1 and C) of SIRT1. Error bars 
signify standard deviation (*p<0.05; **p<0.01; ***p<0.001; *p-values compare treatment 
to respective DMSO control; †p-values compare untreated and DMSO control).
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Figure 21. Resveratrol Activates AMPK. A) Representative immunoblots of P-AMPK and 
AMPK after 2 hours of resveratrol treatment. B) Densitometry quantitation of P-AMPK 
normalized to total AMPK (*p<0.05; **p<0.01; ***p<0.001; *p-values compare treatment 
to respective DMSO control; †p-values compare untreated and DMSO control).
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Figure 22. Resveratrol Does Not Affect Binding of DBC1 & SIRT1. Three independent 
trails of the immunoprecipitation of SIRT1 from cell lysates treated with resveratrol for 2 
hours were conducted. Shown are the immunoblots from each trial probed for both 
SIRT1 to show immunoprecipitation and DBC1 to show any co- immunoprecipitation. Far 
left labels signify the trial number shown. A 1% lysate control and lysate and bead only 
control were included for each trial. 
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Figure 23. SIRT1 & DBC1 Co-immunoprecipitate in MDA-MB-468 cells. Three 
independent trails of the immunoprecipitation of SIRT1 from MDA-MB-468 cell lysates 
treated with resveratrol for 2 hours were conducted. Shown is the immunoblot showing 
each trail (IP 1-3 = immunoprecipitation trail 1-3) probed for both SIRT1 to show 
immunoprecipitation and DBC1 to show any co- immunoprecipitation. A 1% lysate 
control and lysate and bead only control were included. 
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Figure 24. Mechanisms of Resveratrol Induced Apoptosis. A) Possible mechanism of 
100 μM resveratrol treatment where resveratrol activates caspase 3 and 7 to lead to 
apoptosis with no contribution from survivin. B) Possible mechanism of 300 μM 
resveratrol treatment based on the data provided in this study showing the inhibition of 
survivin expression with AMPK activation possibly upstream of survivin. The inhibition of 
survivin allows activated caspase 3 and 7 to cause apoptosis. A “?” implies a gap in 
mechanism understanding. 
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III. RESVERATROL AUGMENTS PACLITAXEL TREATMENT 
 
To determine whether resveratrol treatment could re-sensitize the resistant cells 
to paclitaxel, checkerboard drug combination assays were conducted as previously 
described [231, 232]. The addition of micromolar (2.5-40 μM) amounts of resveratrol 
simultaneously with paclitaxel resulted in a significant lowering of the IC50 value of 
paclitaxel in both MDA-MB-231and MDA-MB-231/PacR cells without any change in 
resveratrol IC50 (Figure 25). By comparing the effects the same ratios had on the 
different cell lines, it appeared that less resveratrol was required to achieve similar fold 
changes in IC50 in the resistant cells compared to the parental cells. A combination 
treatment of 1 part paclitaxel to 2,560 parts resveratrol produced the same IC50 value in 
both the MDA-MB-231 and MDA-MB-231/PacR cells; this IC50 value was significantly 
lower than the IC50 value of paclitaxel alone in MDA-MB-231 cells. In both cells lines, 
there were some ratios that caused a decrease of IC50 value of both drugs, though more 
resveratrol was required in the MDA-MB-231 cells compared to the MDA-MB-231/PacR 
cells to achieve this (Table 1). Most combinations did not give a synergistic effect, but 
rather appear additive or even antagonistic when represented in an isobologram due to 
the IC50 value of resveratrol not decreasing (Figure 26). Some combination ratios 
resulted in similar IC50 values for both cell lines. In contrast, other combination ratios 
significantly decreased the IC50 of the resistant cells but had no effect on the parental 
cells suggesting that resveratrol may act on two different mechanisms to have a 
combination effect, one that is specific to the resistant cells and one common to both 
parental and resistant. Due to these observations, we hypothesized that the mechanism 
of resistance of the MDA-MB-231/PacR cells was important for the effect of resveratrol 
in combination with paclitaxel in these cells. These data were contrary to a previous 
report that showed attenuation of paclitaxel by resveratrol with a 48-hour simultaneous 
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treatment [226]. Interestingly, we see similar attenuation at 24 hours in the MDA-MB-231 
cells at both 10 and 100 μM resveratrol treatment (Figure 27). For the MDA-MB-
231/PacR cells, 10 μM resveratrol treatment has no effect on paclitaxel whereas there is 
no attenuation is seen with 100 μM resveratrol treatment.
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Figure 25. Resveratrol Augments Paclitaxel Treatment in MDA-MB-231 & MDA-MB-
231/PacR Cells. Dose response curves of the constant drug ratios from the 5-day 
checkerboard combination assay in A) MDA-MB-231 and B) MDA-MB-231/PacR cells 
(n=3). Each drug ratio has two graphs one representing the % inhibition versus the 
amount of paclitaxel in the mixture as well as one representing the % inhibition versus 
the amount of resveratrol in the mixture. Standard deviations for individual point were 
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less than 50% (*p<0.05; **p<0.01; ***p<0.001; *p-values compare combination treatment 
IC50 values to the paclitaxel alone treatment IC50 value). 
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Paclitaxel: 
Resveratrol 
Paclitaxel IC50 
(nM) 
Fold Decrease 
compared to 
Paclitaxel Alone 
Resveratrol IC50 
(μM) 
Fold Decrease 
compared to 
Resveratrol Alone 
M
D
A
-M
B
-2
31
 
Alone 4.40 ± 1.49 - 7.79 ± 0.57 - 
1:40960 0.16 ± 0.06*** 28.19 6.39 ± 2.58 1.22 
1:20480 0.41 ± 0.09*** 10.75 8.38 ± 1.83 0.93 
1:10240 0.80 ± 0.11*** 5.53 8.15 ± 1.08 0.96 
1:5120 1.48 ± 0.24*** 2.97 7.60 ± 1.22 1.02 
1:2560 2.42 ± 0.38* 1.82 6.20 ± 0.98 1.26 
1:1280 2.91 ± 0.42 1.51 3.73 ± 0.53* 2.09 
1:640 3.34 ± 0.42 1.32 2.14 ± 0.27** 3.64 
1:320 2.41 ± 0.21* 1.82 0.77 ± 0.07*** 10.08 
 
M
D
A
-M
B
-2
31
/P
ac
R
 
Alone 37.64 ± 13.29 - 9.07 ± 1.57 - 
1:2560 2.52 ± 0.61*** 14.93 6.45 ± 1.57 1.41 
1:1280 6.77 ± 1.23*** 5.56 8.66 ± 1.58 1.05 
1:640 15.28 ± 2.11* 2.46 9.78 ± 1.35 0.93 
1:320 25.67 ± 4.21 1.47 8.21 ± 1.35 1.10 
1:160 35.96 ± 10.01 1.05 5.75 ± 1.60 1.58 
1:80 25.61 ± 9.37 1.47 2.05 ± 0.75*** 4.43 
1:40 2.51 ± 2.57*** 15.00 0.10 ± 0.10*** 90.41 
1:20 0.16 ± 0.27*** 240.95 0.00 ± 0.01*** 2904.51 
 
Table 1. Combination Treatment Decreases Paclitaxel IC50. IC50 values for paclitaxel and 
resveratrol plus or minus the standard deviation and the fold decrease of IC50 compared 
to each drug alone of all combination treatments (*p<0.05; **p<0.01; ***p<0.001; *p-
values compare IC50 values of combination treatment to individual drug alone). 
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Figure 26. The Combination of Resveratrol and Paclitaxel is not Synergistic. 
Isobologram graphs showing the combination effect status of each drug ratio from the 5-
day checkerboard combination assay in A) MDA-MB-231 and B) MDA-MB-231/PacR 
cells. The average IC50 values of resveratrol alone on the y-axis and of paclitaxel alone 
on the x-axis are connected to provide the line of additivity. Each drug ratio is a single 
point based on the average IC50 value for both drugs at this ratio. Any point that falls on 
the line of additivity denotes an additive effect, below the line denotes synergistic effect, 
and above the line denotes an antagonistic effect of the drug combination.
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Figure 27. Resveratrol Can Attenuate Paclitaxel Treatment with Short-term, 
Simultaneous Treatment. Treatment with a 24-hour simultaneous treatment of 100 nM 
paclitaxel treatment with 0, 10, or 100 μM resveratrol. Resveratrol A) attenuates 
paclitaxel in MDA-MB-231 cells and B) has no effect on MDA-MB-231/PacR cells at 10 
μM resveratrol with only a small decrease of growth inhibition at 100 μM resveratrol 
(n=3).  Error bars represent standard deviation (*p<0.05; **p<0.01; ***p<0.001; *p-values 
compare resveratrol treatment to paclitaxel alone treatment). 
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IV. UPREGULATION OF P-GLYCOPROTEIN & CYP2C8 CONTRIBUTES TO 
PACLITAXEL RESISTANCE IN MDA-MB-231/PacR CELLS 
 
To determine the mechanism of resistance in these cells, a commercial PCR 
array for human cancer drug resistance genes was used. Analysis of the PCR array 
identified two genes to be highly upregulated in the resistant MDA-MB-231/PacR cells 
compared to the parental MDA-MB-231 that are known to be factors in paclitaxel 
resistance, ABCB1 and CYP2C8 (Table 2). The full list of genes and the expression 
changes are shown in Appendix A. These two genes were focused on because of their 
known relevance to paclitaxel resistance in breast cancer. The over-expression ABCB1 
and CYP2C8 was validated by real-time RT-PCR and the levels were compared 
between the parental MDA-MB-231 and the MDA-MB-231/PacR or MDA-MB-231/PacR-
Hi cells. ABCB1 was overexpressed in MDA-MB-231/PacR and MDA-MB-231/PacR-Hi 
cells compared to the parental line (Figure 28A). CYP2C8 was also significantly 
upregulated in both cells lines compared to the parental cells (Figure 28B). Interestingly, 
there was also a significantly higher expression of CYP2C8 in the MDA-MB-231/PacR 
cells compared to the MDA-MB-231/PacR-Hi cells.  
Finally, the functional importance of the gene expression data was tested with 
inhibitors of the protein products of the genes. Verapamil was used to inhibit P-gp, the 
protein product of ABCB1; and trimethoprim was used to selectively inhibit CYP2C8 
[239]. Inhibition of P-gp or CYP2C8 alone decreased the resistance of the MDA-MB-
231/PacR cells to paclitaxel, as measured by proliferation assays (Figure 29). The 
paclitaxel IC50 for MDA-MB-231/PacR cells alone was 61 nM. After trimethoprim 
treatment, the IC50 decreased to 40 nM. After verapamil treatment the IC50 decreased to 
8 nM. Simultaneous inhibition of both P-gp and CYP2C8 did not further lower the IC50 
value of the MDA-MB-231/PacR cells at 9 nM, likely because verapamil alone lowered 
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the paclitaxel IC50 to nearly that of the parental MDA-MB-231 cells, which is 5 nM. 
Interestingly, only inhibition of P-gp significantly decreased the resistance to paclitaxel of 
the MDA-MB-231/PacR-Hi cells from the paclitaxel IC50 of 117 nM to 12 nM. There was 
no statistical difference between the paclitaxel IC50 of MDA-MB-231 and the IC50 values 
of the MDA-MB-231/PacR or MDA-MB-231/PacR-Hi cells after verapamil or the 
verapamil and trimethoprim treatment. Additionally, there were no differences between 
the paclitaxel IC50 values in any of the cells lines between the verapamil and the 
verapamil and trimethoprim treatments. Therefore, it seems that although P-gp, 
CYP2C8, and possibly other factors are relevant to the resistance, P-gp is likely the 
more important factor in both the MDA-MB-231/PacR and MDA-MB-231/PacR-Hi cells. 
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Symbol Description Function 
Fold Change T-TEST 
Fold Up- or Down-
Regulation 
MDA-MB-
231/PacR /  
MDA-MB-231 
p-value
a
 
MDA-MB-
231/PacR / MDA-
MB-231 
ABCB1 
ATP-binding cassette, sub-family B 
(MDR/TAP), member 1 
Xenobiotic 
metabolism 
181.99 0.21 181.99 
CYP2C8 
Cytochrome P450, family 2, subfamily 
C, polypeptide 8 
Xenobiotic 
metabolism 
12.51 0.16 12.51 
CYP1A1 
Cytochrome P450, family 1, subfamily 
A, polypeptide 1 
Xenobiotic 
metabolism 
5.06 0.16 5.06 
ATM Ataxia telangiectasia mutated S/T protein kinase 3.35 0.01 3.35 
TNFRSF11A 
Tumor necrosis factor receptor 
superfamily, member 11a 
NFKB activator 3.11 0.00 3.11 
APC Adenomatous polyposis coli Tumor repressor 3.11 0.05 3.11 
 
CYP2E1 
Cytochrome P450, family 2, subfamily 
E, polypeptide 1 
Xenobiotic 
metabolism 
0.03 0.01 -31.07 
ERBB4 
V-erb-a erythroblastic leukemia viral 
oncogene homolog 4 (avian) 
Receptor tyrosine 
kinase 
0.15 0.02 -6.71 
AR Androgen receptor 
Androgen 
receptor 
0.21 0.04 -4.80 
ABCC3 
ATP-binding cassette, sub-family C, 
member 3 
Xenobiotic 
metabolism 
0.23 0.14 -4.27 
ABCG2 
ATP-binding cassette, sub-family G, 
member 2 
Xenobiotic 
metabolism 
0.24 0.11 -4.11 
FOS 
FBJ murine osteosarcoma viral 
oncogene homolog 
Transcription 
factor 
0.32 0.06 -3.16 
aP-values were calculated with a Student’s T-Test of the replicate 2^(- ΔCt) values for each gene 
Table 2. PCR Array Identified Two Genes, ABCB1 & CYP2C8, Implicated in Breast 
Cancer Paclitaxel Resistance.
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Figure 28. ABCB1 & CYP2C8 are overexpressed in MDA-MB-231/PacR & MDA-MB-
231/PacR-Hi Cells. Fold change of gene expression from qPCR measuring mRNA levels 
in MDA-MB-231/PacR and MDA-MB-231/PacR-Hi cells compared to MDA-MB-231 cells 
A) of ABCB1 B) of CYP2C8 (n=3). Error bars signify standard deviation. P-values were 
calculated with a Student’s T-Test of the replicate 2^(- ΔCt) values for each gene and 
compare resistant cell line to parental line (*p<0.05; **p<0.01; ***p<0.001; * p-value 
compares fold changes of each resistant line and the parental line; † p-value compares 
fold changes of MDA-MB-231/PacR to that of MDA-MB-231/PacR-Hi).
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Figure 29. Inhibition of P-glycoprotein & CYP2C8 Re-sensitize MDA-MB-231/PacR Cells 
to Paclitaxel. The 5-day IC50 values for MDA-MB-231, MDA-MB-231/PacR and MDA-
MB-231/PacR-Hi cells with paclitaxel alone or in simultaneous combination with the P-gp 
inhibitor, verapamil (1 μM), the CYP2C8 inhibitor, trimethoprim (25 μM), or both (n=3). 
Error bars signify standard deviation (*p<0.05; **p<0.01; ***p<0.001; *p-values compare 
inhibitor treatment to paclitaxel alone treatment). There was no statistical difference 
between the MDA-MB-231 and MDA-MB-231/PacR or MDA-MB-231/PacR-Hi cells after 
verapamil or the verapamil and trimethoprim treatment. Additionally, there were no 
differences between any of the cells lines between the verapamil and the verapamil and 
trimethoprim treatments
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CHAPTER 4: DISCUSSION and FUTURE DIRECTIONS 
 
I. RESISTANT CELLULAR MODEL GENERATION 
 
A novel, paclitaxel-resistant TNBC cell line was successfully developed with a 
12-fold resistance to paclitaxel compared to parental cells. The intermittent, stepwise 
treatment method (Figure 7) developed a more resistant and better growing population 
of resistant cells compared to a continuous treatment method. Furthermore, this 
intermittent treatment method mimics acquired paclitaxel resistance that can occur in 
patients after intermittent paclitaxel treatment of a primary tumor where any remaining 
cancer cells are paclitaxel resistant and can then recur as a paclitaxel-resistant tumor. 
Clinically relevant acquired drug resistance spans from 2- to 12-fold increased 
resistance compared to cells from tumors prior to treatment [240]. Therefore, this cellular 
model more closely mimics what is observed clinically when compared to other 
laboratory models, where resistance is so high it is not clinically meaningful [240]. 
Importantly, this clinically relevant resistance is maintained though the cells are no 
longer cultured in paclitaxel unlike other paclitaxel-resistant cell lines that must be 
continuously grown in the presence of the drug to maintain resistance [240]. Though 
generated cellular models are useful for studying cancer resistance, it is important that 
results from such a model system are further studied for their clinical relevance [37]. 
 
II. RESVERATROL INDUCES CELL PROLIFERATION INHIBITION, SENESCENCE, 
AND APOPTOSIS 
 
The data presented here suggest that resveratrol induces cell proliferation 
inhibition, senescence, and apoptosis in TNBC cells regardless of paclitaxel sensitivity. 
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The low R2 value, the correlation coefficient of the line of best fit, of the clone paclitaxel 
and resveratrol IC50 values analysis indicates that there is no correlation between 
paclitaxel resistance and resveratrol sensitivity (Figure 8). Furthermore, there was no 
statistically significant difference between the paclitaxel-resistant and -sensitive cells in 
any of the studies conducted with resveratrol alone.  
In MDA-MB-231 and MDA-MB-231/PacR cells, resveratrol inhibited cell 
proliferation and induced senescence and apoptosis (Figures 9-22). In cell count 
proliferation (Figure 9) and colony formation assays (Figure 10), 100 μM resveratrol 
treatment completely inhibited the ability of the parental and resistant cells to proliferate. 
In the cell count assay, 10 μM resveratrol treatment significantly decreased proliferation 
in both cell lines (Figure 9) but only significantly decreased colony formation in the 
resistant cells in the survival assay (Figure 10A). The differential effect of colony 
formation at 10 μM resveratrol between the two methods suggests resveratrol may affect 
the ability of MDA-MB-231/PacR, but not MDA-MB-231, cells to attach to the plate after 
treatment. In addition, the proliferation data suggest that although 10 μM resveratrol was 
able to inhibit proliferation after 3 days (Figure 9), this effect was not irreversible as 
evidenced by the ability of colonies to form after removal of resveratrol (Figure 10). This 
is in contrast to the effect of 100 μM resveratrol treatment, where cell counts showed 
that cells plated were still attached to the plate though they had not proliferated. 
Resveratrol alone did not induce cell cycle arrest (Figure 11), which has 
previously been shown in multiple cancer cell lines [161]. It is possible, however, that 
arrest was missed and occurred before the Sub-G1 accumulation occurred with 300 μM 
resveratrol at 48 hours, as no other time points were assessed. Additionally, it is 
possible that lower concentrations including, 10 and 100 μM, of resveratrol would have 
shown cell cycle arrest at time points longer than 48 hours. Interestingly, a peak was 
observed in both cell populations that may suggest micronucleation in these cells. As 
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discussed previously, micronucleated cells can accumulate between G1 and S phase as 
well as after G2/M phase due to their DNA content [236]. Though we did find the 
presence of micronucleated cells in the untreated cell lines (Figure 12), measuring the 
increase of micronucleation after 300 μM resveratrol treatment using 
immunofluorescence was not possible as very few cells remain attached to a slide. 
Micronucleated cells, a sign of genotoxic stress, are common in cancer cell populations; 
however, the fate of micronucleated cells is unclear. Micronuclei may re-incorporate into 
the nucleus, the cell may destroy the micronucleus and continue to proliferate though 
divisions are likely limited, or cell may undergo apoptosis [241]. Consequently, the 
significance of resveratrol treatment increasing miconucleation is uncertain. 
In the context of the senescence and apoptosis data, the proliferation and cell 
cycle data is further explained. After 3 days of treatment, 37% of MDA-MB-231 and 38% 
of MDA-MB-231/PacR cells treated with 100 μM resveratrol were senescent (Figure 13). 
As senescent cells can arrest in G1, G2/M or S phase [194], this increase in senescence 
can explain why there is no cell proliferation and no cell cycle arrest concurrently. 
Additionally, at the same 3-day time point, 31% of MDA-MB-231 and 19% of MDA-MB-
231/PacR cells treated with 100 μM resveratrol are undergoing apoptosis (Figure 14). 
Therefore, after 3 days of 100 μM resveratrol treatment, approximately 60% of both cell 
lines have lost their ability to proliferate as they are either senescent or apoptotic. It is 
also possible that by 3 days after treatment, there is also some cell cycle arrest or 
autophagy that explains why the remaining cells are not proliferating according to the 
cell proliferation data. In further support of additional mechanisms of action, 10 μM 
resveratrol treatment in both cell lines showed no cell cycle arrest and little senescence 
induction while cell proliferation was significantly inhibited, though this proliferation 
inhibition was partially reversible as suggested by colony formation. By 5 days after 100 
μM resveratrol treatment, 64% and 53% of MDA-MB-231 and MDA-MB-231/PacR cells, 
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respectively, have undergone apoptosis, and so nearly all cells in both cell lines are not 
able to divide. After 48 hours of 300 μM resveratrol treatment, 49% and 34% of MDA-
MB-231 and MDA-MB-231/PacR cells respectively, accumulated in Sub-G1 phase, 
which is consistent with late apoptosis (Figure 12). Correspondingly, the apoptosis data 
shows that by 3 days 300 μM resveratrol treatment, nearly all of the cells in both cell 
lines are in either early or late apoptosis (Figure 14). 
Though the method of measuring apoptosis used in this study cannot distinguish 
between late apoptosis and necrosis, the presence of early apoptosis and the activation 
of caspase 3 and caspase 7 indicate that the cells are likely undergoing apoptosis. With 
300 μM resveratrol treatment, a large activation of caspase 7 can be seen at 48 hours. 
For 100 μM resveratrol treatment, caspase 7 activation began at 48 hours (Figure 15) 
and increased through 3 and 5 days suggesting a slow acting caspase response (Figure 
16). In contrast, the 48-hour caspase 3 data suggest this time point is likely the end of 
activation as none is seen at 3 or 5 days, and so this is a faster process than caspase 7 
activation (Figure 17). In addition, these data imply caspase 3 is less important than 
caspase 7 in the 100 μM resveratrol as procaspase 3 never decreases and cleaved 
caspase 3 was never detected at this treatment concentration. It is important to note that 
the early and late apoptosis seen at 5 days may represent the heterogeneity of the cell 
population as this time point would suggest delayed onset apoptosis or other forms of 
cell death such as autophagy or necroptosis. 
The mechanism of resveratrol-induced apoptosis in this model does not appear 
to be dependent on the decrease of survivin expression, though a dose-dependent 
decrease of survivin has been shown in multiple other human cancer cell lines [212, 
242-244]. Survivin protein levels were only decreased by 300 μM resveratrol treatment 
(Figure 18). This decrease was complete by 48 hours and was sustained at least 
through 5 days. Treatment with 100 μM resveratrol did not decrease survivin even after 
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5 days. This is interesting because while apoptosis was observed at 3 and 5 days of 100 
μM treatment, there was no significant difference in survivin protein levels, suggesting 
survivin may not be critical in resveratrol-induced apoptosis in these cells at this lower 
concentration (Figure 18C-D). It is possible there is a dose-dependent relationship with a 
small window of efficacy between 100 and 300 μM, but it is also possible the decrease is 
an off-target effect of resveratrol. Importantly, knockdown of caspase 7 did not result in 
any recovery of survivin protein levels (Figure 19), which implies that the decrease of 
survivin is not due to the cleavage activity of caspase 7 leading to the degradation of 
survivin protein, which is further supported by the fact that although caspase 7 activation 
is seen after 3 and 5 days of 100 μM resveratrol treatment, there is no decrease of 
survivin levels. Therefore, survivin may only play a role at high concentration resveratrol 
treatment or may be an off-target effect of resveratrol in these cells.  
Resveratrol did not affect protein levels of SIRT1 or DBC1 (Figure 20) but did 
activate AMPK (Figure 17), as expected if resveratrol were activating SIRT1 by 
interrupting the binding of SIRT1 and DBC1. However, we observed little to no binding 
between SIRT1 and DBC1 in the MDA-MB-231 cells (Figure 22) in accordance with a 
previous study which determined the amount of binding between SIRT1 and DBC1 in 
various breast cancer cell lines [245]. However, some stronger binding between SIRT1 
and DBC1 was seen in the MDA-MB-231/PacR cells though this binding was very erratic 
across independent experiments, making this data difficult to interpret. To ensure the 
results seen were not due to an ineffective protocol, the experiment was repeated with a 
cell line recognized by Sung et al. to have association between SIRT1 and DBC1. MDA-
MB-468 cells showed much more consistent binding between SIRT1 and DBC1 
suggesting that the lack of binding in the co-immunoprecipitation experiment in MDA-
MB-231 was due to little SIRT1 and DBC1 association (Figure 23). However, this does 
not explain the erratic binding seen in and MDA-MB-231/PacR cells. Together these 
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data suggest the mechanism of resveratrol-induced apoptosis in these cells is not 
dependent on decreased survivin expression, changes in SIRT1 and DBC1 levels, nor 
the binding of SIRT1 and DBC1. However, it is possible that resveratrol acts through 
SIRT1 activation in these cells by allosteric activation [246] or altering SIRT1 localization 
[247]. These data provide a mechanism that is still not clearly understood (Figure 24). 
Taken together, these studies on the efficacy and mechanism of resveratrol in 
this cellular model of paclitaxel-sensitive and -resistant TNBCs point out that resveratrol 
is capable of inhibiting cell proliferation at low micromolar amounts and causes 
apoptosis at higher concentrations. Although the mechanism of resveratrol-induced 
apoptosis is not completely understood, it is possible that survivin and SIRT1 play a role 
as suggested previously [212]. Notably, the effects of resveratrol were not significantly 
different between the paclitaxel-resistant and -sensitive cells, suggesting resveratrol may 
be useful in treating TNBCs regardless of paclitaxel sensitivity. 
These findings highlight the need for further examination of the mechanism of 
resveratrol as a single agent in these cell lines. It is possible that the cells accumulated 
after G2/M phase as well as in S phase are micronucleated cells. Whether the 
population is indeed micronucleated cells could be determined with simultaneous flow 
cytometry and imaging. This method combined with cell sorting may also help determine 
what the fate of the cells may be and how it is important in the context of resveratrol 
treatment. In addition, a more complete time course of cell cycle analysis after 
resveratrol treatment would further elucidate the timeline of resveratrol effects. 
Determination of possible autophagy caused by resveratrol could explain the gap in cell 
proliferation, senescence and apoptosis data. Further examination to better understand 
what role, if any, survivin has in resveratrol treatment is also needed. Whether there is a 
dose-dependent response between 100 and 300 μM concentrations of resveratrol can 
be determined with immunoblotting, and whether survivin is required for resveratrol-
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induced apoptosis can be assessed with stable survivin knockdowns. However, further 
survivin studies will not provide information on the mechanism of resveratrol-induced 
apoptosis at 100 μM treatment as survivin does not appear to important at this 
concentration. Therefore, further studies need to be conducted to determine the 
mechanism of resveratrol at this lower concentration as well. Considering previous work 
on resveratrol action, there are many possibilities for this mechanism that can be 
explored, though perhaps the most likely to be important in this model are activation of 
ceramide synthesis [207] and inhibition of NF-κB promoter activity [208] as these have 
been shown to be important factors in MDA-MB-231 cells. Ceramide is important 
mediator in cellular stress response, and the accumulation of ceramide is growth 
inhibitory and pro-apoptotic [248]. The inhibition of the oncogenic NF-κB, which is 
constitutively activated in MDA-MB-231 cells and many other cancers, can promote 
cancer cells to stop proliferating or undergo apoptosis [249]. Finally, there is currently no 
way to directly measure SIRT activity within a cell line, which makes determining 
resveratrol action on SIRT1 difficult. A common measure of SIRT1 activity in cells is to 
measure the amount of p53 that is acetylated using immunobloting with an antibody 
specific for aceteylated p53; lower acetylation of p53 suggests higher SIRT1 activity as 
p53 is a substrate for SIRT1. This method was attempted in the present study without 
success, possibly due to the mutated p53 in the cells. A fluorometric assay using a cell 
extract can measure SIRT1 activity directly; however, in the presence of resveratrol, the 
fluorescent probe has been shown to affect the results of these assays [250]. An 
important study would be the examination of the acetylation status of the survivin 
promoter after resveratrol treatment if survivin is shown to be important in resveratrol-
induced apoptosis. A decrease of acetylation would be good evidence of SIRT1 
activation by resveratrol as has been previously shown [212]. In addition to this, SIRT1 
knockdown would determine the importance of SIRT1 in resveratrol-induced apoptosis. 
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Therefore, chromatin immunoprecipitation and stable SIRT1 knockdown would be the 
best options for further experiments into SIRT1 activation by resveratrol.  
 
III. RESVERATROL AUGMENTS PACLITAXEL TREATMENT 
 
Importantly, our data show that resveratrol can augment the effects of paclitaxel 
when used in simultaneous combination (Figure 25). This is contrary to a previous report 
showing resveratrol to attenuate paclitaxel treatment in MDA-MB-231 cells [226]. 
Interestingly, Fukui et al. used a 48-hour simultaneous treatment, and previous 
experiments from the present study showed a 24-hour time point of resveratrol treatment 
either had no effect or caused similar attenuation of paclitaxel treatment (Figure 27). The 
present study suggests at a 5-day time point resveratrol enhances paclitaxel treatment. 
The IC50 values of paclitaxel for both the parental and the resistant cells were lowered 
significantly with the addition of resveratrol. Notably, addition of resveratrol decreased 
the paclitaxel IC50 value of the resistant MDA-MB-231/PacR cells to the IC50 value of the 
parental line. Moreover, the IC50 value could be lowered below that of the parental line 
with more resveratrol. A trend emerged in these data suggesting the more resveratrol 
that there is in the combination solution, the lower the resulting paclitaxel IC50 value. This 
was true in both the parental and the resistant cells. It is most likely that higher amounts 
of resveratrol in the MDA-MB-231/PacR cells could lower the IC50 of paclitaxel to similar 
levels as the combination treatment achieved in the MDA-MB-231 cells. In addition, 
lower concentrations of resveratrol decreased the IC50 value of both drugs compared to 
the single drugs alone (Table 1). In fact, with concentrations of resveratrol and paclitaxel 
similar to those used by Fukui et al., this study shows that after 5 days the combination 
of resveratrol and paclitaxel is synergistic (Figure 26). It is important to note that 
although the isobologram analysis shows that these combinations are largely 
95 
 
antagonistic (Figure 26), this was due to the resveratrol IC50 remaining the same while 
the paclitaxel IC50 decreased. Consequently, this is not the most useful measure of 
combination success in these circumstances. Critically, the fact that synergy was not 
widely achieved is not of concern as a desirable decrease of paclitaxel IC50 was 
achieved and necessary amounts of resveratrol are attainable and well tolerated in 
humans as well as inexpensive. Both high concentrations of resveratrol decreasing the 
paclitaxel IC50 with no change in resveratrol IC50 and lower concentrations of resveratrol 
decreasing both paclitaxel and resveratrol IC50 could be useful clinical tools. 
Interestingly, some ratios that significantly lowered the resistance of the MDA-MB-
231/PacR cells had no effect on the parental cells. Considered in the context of the trend 
of the data, this suggests resveratrol may be acting of two different mechanisms; one 
that is specific to the resistance of the cells and one that is common to both the parental 
and resistant cells. Together, these data suggest resveratrol could be used to treat 
TNBCs in combination with paclitaxel to sensitize paclitaxel-resistance cancers and 
decrease the dose of paclitaxel needed without changing the efficacy of treatment. This 
proposed regimen could potentially both improve outcomes for patients with paclitaxel-
resistant cancers and decrease the general toxicity caused by paclitaxel in patients with 
both paclitaxel-resistant and -sensitive cancers. 
Further combination studies are needed to ensure the trend is correct and the 
effects of higher amounts of resveratrol in MDA-MB-231/PacR cells as well as the 
effects of lower amounts of resveratrol in MDA-MB-231 cells. It will be important to 
determine if the combination of resveratrol and paclitaxel not only inhibits cell 
proliferation, as was estimated with the checkerboard combination assay, but also 
induces apoptosis. Whether the combination can only inhibit growth or can also induce 
apoptosis will have important implications in the clinical use of the combination. Better 
understanding of the combination effect will help determine the correct treatment 
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administration and regimen for in vivo studies, which will need to be conducted to 
demonstrate that the combination is effective in tumors. Determination of the 
combination mechanism will also be important in order to provide a pharmacodynamic 
target that can then be used in animal and human studies to ensure that the intended 
target is hit by the treatment. 
Due to the classification of resveratrol as a dietary supplement, clinical trials are 
a possibility. However, there are important points to consider before human trials are 
attempted. The first consideration is that, although resveratrol alone is very well tolerated 
in humans, it is possible that the combination of resveratrol and paclitaxel could increase 
the toxicity of paclitaxel. Due to the possibility of increasing paclitaxel accumulation by 
decreasing P-gp expression, liver toxicity is of concern. Importantly, liver toxicity can be 
closely monitored in human subjects. Perhaps of greatest concern is the dose limiting 
neurotoxicity of paclitaxel and the effects of the combination treatment on peripheral 
neurons, which can be tested in vitro using either dorsal root ganglia from rats or those 
derived from induced pluripotent stem cells from humans. Furthermore, as a possible 
alternative to doing the extensive mouse studies before clinical trials, the cells used in 
this study could be used in 3-dimentional cultures to better estimate the in vivo relevance 
of the combination study. Cells are grown in matrigel or low-attachment dishes with 
serum free media containing growth factors to promote proliferation and will form 
mammospheres in the media [251]. The mammary stem cells in the culture created 
provide the multiple cell types and the structure of a tumor that would be present in vivo 
[252]. This system mimics tumor drug delivery and effects more closely than cells grown 
in 2-dimentional cultures [252]. 
However, the determination of efficacy and toxicity in mice may still be a critical 
step between cell line and human studies. For these studies, the formulation of 
resveratrol will have to be carefully considered prior to these in vivo studies. In addition, 
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pilot studies would need to be conducted to determine any changes in pharmacokinetics 
when the drugs are combined and the best administration method of resveratrol, oral 
gavage, which mimics oral dosing in humans, or intraperitoneal injection, which is 
common among resveratrol studies. It is likely that daily dosage of resveratrol would be 
used due the pharmacokinetic properties, and that paclitaxel in PBS would be 
administered as an intraperitoneal injection once a week as this regimen is commonly 
used in mice as it mimics the dosing in humans. Depending on whether the treatment 
proves to inhibit cell proliferation only or also causes apoptosis will dictate whether these 
studies focus on prevention of tumor growth or also tumor shrinking. These studies 
would likely be conducted with orthotopic xenograft mouse models implanting the cells 
used in this study into the mammary fat pad of the highly immunodeficient NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice [253] and comparing parental and resistant cells, as 
well as mice treated with vehicle, paclitaxel, resveratrol or a combination of paclitaxel 
and resveratrol. As an alternative to this model, a more clinically relevant model may be 
patient-derived xenografts, where human breast tumor tissue samples are implanted into 
the mammary fat pad of mice [254]. 
 
IV. UPREGULATION OF P-GLYCOPROTEIN & CYP2C8 CONTRIBUTES TO 
PACLITAXEL RESISTANCE IN MDA-MB-231/PacR CELLS 
 
These data show ABCB1 and CYP2C8 genes were highly overexpressed in the 
resistant cells compared to the parental cells (Table 2, Figure 28). These two genes 
were focused on because of their known relevance to paclitaxel resistance in breast 
cancer; however, other genes identified by the PCR array may also play a role in the 
resistance mechanism. Only the genes represented in Table 2 will be further discussed 
here; see Appendix A for all genes tested. It is unlikely that CYP1A1 as it has no 
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reported connection of paclitaxel resistance. However, it is possible that the decrease of 
CYP2E1 plays some role as it has been reported that the presence of CYP2E1 can 
augment paclitaxel [255]. Though the over expression of ABCC3 and ABCG2 has been 
shown to confer paclitaxel resistance in cancer cells [256, 257], the expression of these 
genes decreases in the resistant cells compared to the parental cells. The increased 
expression of NFκB activator, TNFRSF11A, should not be relevant as NFκB is 
constitutively active in these cells [258]. The remaining gene changes in Table 2, ATM, 
APC, ERBB4, AR, and FOS, have not been shown to be relevant to triple negative 
breast cancers. Therefore, the overexpression of the ABCB1 and CYP2C8 genes are 
the most likely factors to be importantin the resistance mechanism. 
The product of ABCB1, P-gp, is an efflux pump that can remove paclitaxel from 
cells. CYP2C8 is the main metabolizing enzyme for paclitaxel that forms a 30-fold less 
active metabolite, 6α-OHP [123]. Interestingly, though overexpression of CYP2C8 has 
previously shown to be involved in paclitaxel resistance, this was a transient induction 
that was reversed when the cells were no longer grown in the presence of paclitaxel 
[137], which is contrary to the more permanent gene amplification seen in this cell model 
of paclitaxel resistance. The increased expression of P-gp and CYP2C8 could allow 
these resistant cells to both pump paclitaxel out more quickly and to break it down to a 
less active metabolite more efficiently than the parental line. This effect would prevent 
the accumulation of paclitaxel in the cell, resulting in the need for much higher 
concentrations of paclitaxel to kill the cells. Importantly, inhibition of P-gp resulted in a 
decrease of paclitaxel resistance of MDA-MB-231/PacR and MDA-MB-231/PacR-Hi cells 
(Figure 26). Interestingly, inhibition of CYP2C8 was capable of decreasing the paclitaxel 
resistance of MDA-MB-231/PacR cells but not MDA-MB-231/PacR-Hi cells. Considering 
that the MDA-MB-231/PacR-Hi cells have higher resistance, lower CYP2C8 gene 
expression, and less sensitivity to the CYP2C8 inhibitor compared to the MDA-MB-
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231/PacR cells implies that CYP2C8 is a less important factor in the mechanism of 
paclitaxel resistance than P-gp. Additionally, the MDA-MB-231/PacR cells may have 
another factor contributing to resistance, as verapamil did not entirely remove paclitaxel 
resistance though higher verapamil may have removed all resistance. Collectively, these 
results suggest upregulation of P-gp is the most important factor in the paclitaxel 
resistance of these cells and pharmacological inhibition of P-gp can overcome the 
paclitaxel resistance acquired in these cells. 
Resveratrol has been shown to decrease the formation of the less active 6α-
OHP, the main paclitaxel metabolite formed by CYP2C8 [259]. And, critically, resveratrol 
has been shown to inhibit ABCB1 gene expression in multiple cancer cell models and, 
thereby, increase cellular accumulation of P-gp substrate drugs [222, 260-262]. These 
mechanisms may explain the re-sensitizing ability of resveratrol to lower the paclitaxel 
IC50 in the resistant cells. Importantly, the inhibitors for P-gp and CYP2C8 do not affect 
the paclitaxel IC50 in the parental cells (Figure 29) suggesting that the function of P-gp 
and CYP2C8 are not important to paclitaxel sensitivity in the parental cells, which further 
supports the suggestion that there is a mechanism of the resveratrol-paclitaxel 
combination that is independent of the mechanism by which resveratrol re-sensitizes the 
resistant cells to paclitaxel. 
Based on our findings, it will be important to validate that resveratrol is affecting 
the function of P-gp and CYP2C8 as well as paclitaxel accumulation in these cells using 
functional assays. Determination of increased P-gp protein levels is important and was 
attempted in this study. However, the immunoblotting was not successful and needs to 
be further optimized. To ensure the importance of ABCB1 gene expression, qPCR of 
resveratrol treated MDA-MB-231/PacR cells should be conducted to determine whether 
resveratrol treatment decreases ABCB1 gene expression in these cells alone and in 
combination with paclitaxel. Further, a fluorescent paclitaxel accumulation assay using 
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labeled paclitaxel, Oregon green 488 paclitaxel, can be conducted to determine 
accumulation in cells and efflux into media in the cells alone and with simultaneous 
resveratrol treatment. To determine the importance of CYP2C8, a fluormetric CYP2C8 
assay can be conducted using dibenzylfluoresin, which is cleaved to a fluorescent 
metabolite by CYP2C8, CYP2C9, CYP2C19 and CYP3A4. This reagent should show the 
difference in CYP2C8 metabolism because, of the cytochromes that cleave this 
substrate, only CYP2C8 was shown to be different between the parental and resistance 
cells in the PCR array. These studies will be particularly important for predicting whether 
the combination of resveratrol and paclitaxel will increase toxicities in vivo. If resveratrol 
increases paclitaxel accumulation, it is possible that higher paclitaxel accumulation could 
occur in other tissues that highly express P-pg and CYP2C8, such as the liver, which 
could lead to an increase in paclitaxel toxicity. In addition, genetic manipulation of both 
cell lines will be necessary to ensure the importance of these genes in the resistance. 
Both knocking out expression in the resistant cells and overexpressing the genes in the 
parental cells would be necessary to show these genes are critical for resistance in this 
model.  
Furthermore, any additional mechanisms that could account for the combination 
effect of resveratrol and paclitaxel seen in the parental cells need to be elucidated. The 
data suggest that resveratrol is acting on two different mechanisms, one to decrease the 
resistance of the resistant cells and another to further sensitize resistant and parental 
cells to paclitaxel. This data will also be important in determining whether this 
combination therapy will only be useful in TNBCs or in other cancers as well. 
Considering data from other cancer cell lines showing a positive resveratrol and 
paclitaxel combination, it is possible the decrease of Bcl-xL [219] or Bcl-2 [222] or the 
increase of p21 expression could be involved in promoting paclitaxel-induced apoptosis 
[220].
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SUMMARY 
 
A novel paclitaxel-resistant TNBC cell line was developed with a stable and 
clinically relevant resistance. The paclitaxel resistance had no effect on resveratrol 
efficacy. Resveratrol was capable of inhibiting cell proliferation and causing apoptosis in 
TNBC cells regardless of paclitaxel sensitivity. Importantly, resveratrol augmented 
paclitaxel treatment in both paclitaxel-sensitive and paclitaxel-resistant TNBC cells in 
vitro. The effect of resveratrol on the paclitaxel sensitivity of the resistant cells may be 
linked to the known ability of resveratrol to inhibit P-gp and CYP2C8 both of which were 
found to be involved in the paclitaxel-resistance of our model. Overall these data show 
for the first time that resveratrol can re-sensitize resistant TNBC cells to paclitaxel and 
can decrease the concentration of paclitaxel needed to produce the same effect as 
paclitaxel alone. 
This study has some noteworthy limitations. Perhaps the most important 
limitation is the use of a laboratory generated cell line model of paclitaxel resistance, the 
properties of which may or may not correlate with the clinical presentation of paclitaxel 
resistance. In addition, although resveratrol was shown to induce cell proliferation 
inhibition, senescence, and apoptosis, the mechanism of resveratrol in these cells is still 
not completely understood. Furthermore, resveratrol clearly augments paclitaxel 
treatment in these TNBC cells, though the mechanism of the combination is unknown. 
Finally, this study does not address the global applicability of this treatment for cancers 
and so may prove to only be useful in a very small subset of patients 
This study has raised many questions that need to be answered. The most 
critical of which are the mechanism of action of the combination and whether resveratrol 
augments paclitaxel treatment in vivo. It will be necessary to determine whether the 
resistance of the resistant cells is due to the inhibition of paclitaxel accumulation, and 
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whether resveratrol acts in these cells by increasing drug accumulation. In addition, the 
mechanism of resveratrol and paclitaxel combination that is common to both the parental 
and resistant cells will have important implications for the clinical application of this 
combination. A clinical trial is a possibility due to the classification of resveratrol as a 
dietary supplement. However, toxicity studies using 2- and 3-dimentional cell culture, 
studies identifying pharmacodynamic targets, and perhaps also animal studies will be 
important steps between cell line studies and human trials because there is a possibility 
that the combination could increase paclitaxel toxicity particularly in tissues that highly 
express P-gp, such as the liver and in peripheral neurons. The most critical studies will 
be the combination treatment in patients with TNBC and, depending on the mechanism 
of the combination, other cancers as well. This work and the questions it has raised have 
the important clinical implication that resveratrol may be a useful clinical tool as a single 
agent or in combination with paclitaxel for patients with TNBC to reverse paclitaxel 
resistance as well as decrease the dosages of highly toxic paclitaxel administered 
without affecting efficacy. 
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APPENDIX: Complete PCR Array Data 
Symbol Description 
Fold 
Change T-TEST 
Fold Up- or 
Down-
Regulation 
MDA-MB-
231/PacR / 
MDA-MB-
231 
p-value 
MDA-MB-
231/PacR / 
MDA-MB-
231 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 181.99 0.21 181.99 
ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 0.60 0.94 -1.65 
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 0.70 0.81 -1.43 
ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 0.23 0.14 -4.27 
ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 1.07 0.44 1.07 
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 0.24 0.11 -4.11 
AHR Aryl hydrocarbon receptor 0.59 0.83 -1.70 
AP1S1 Adaptor-related protein complex 1, sigma 1 subunit 0.86 0.65 -1.16 
APC Adenomatous polyposis coli 3.11 0.05 3.11 
AR Androgen receptor 0.21 0.04 -4.80 
ARNT Aryl hydrocarbon receptor nuclear translocator 1.83 0.32 1.83 
ATM Ataxia telangiectasia mutated 3.35 0.01 3.35 
BAX BCL2-associated X protein 0.99 0.46 -1.01 
BCL2 B-cell CLL/lymphoma 2 1.17 0.34 1.17 
BCL2L1 BCL2-like 1 0.64 0.75 -1.56 
BLMH Bleomycin hydrolase 0.79 0.79 -1.27 
BRCA1 Breast cancer 1, early onset 1.15 0.47 1.15 
BRCA2 Breast cancer 2, early onset 1.13 0.45 1.13 
CCND1 Cyclin D1 0.78 0.70 -1.28 
CCNE1 Cyclin E1 0.87 0.90 -1.15 
CDK2 Cyclin-dependent kinase 2 2.60 0.19 2.60 
CDK4 Cyclin-dependent kinase 4 1.74 0.40 1.74 
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 0.83 0.71 -1.21 
CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 2.15 0.06 2.15 
CDKN2A Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) N/A N/A N/A 
CDKN2D Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 0.93 0.60 -1.08 
CLPTM1L CLPTM1-like 0.74 0.61 -1.35 
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 5.06 0.16 5.06 
104 
 
Symbol Description 
Fold 
Change T-TEST 
Fold Up- or 
Down-
Regulation 
MDA-MB-
231/PacR / 
MDA-MB-
231 
p-value 
MDA-MB-
231/PacR / 
MDA-MB-
231 
CYP1A2 Cytochrome P450, family 1, subfamily A, polypeptide 2 2.67 0.58 2.67 
CYP2B6 Cytochrome P450, family 2, subfamily B, polypeptide 6 2.14 0.22 2.14 
CYP2C19 Cytochrome P450, family 2, subfamily C, polypeptide 19 1.51 0.28 1.51 
CYP2C8 Cytochrome P450, family 2, subfamily C, polypeptide 8 12.51 0.16 12.51 
CYP2C9 Cytochrome P450, family 2, subfamily C, polypeptide 9 2.28 0.12 2.28 
CYP2D6 Cytochrome P450, family 2, subfamily D, polypeptide 6 2.00 0.16 2.00 
CYP2E1 Cytochrome P450, family 2, subfamily E, polypeptide 1 0.03 0.01 -31.07 
CYP3A4 Cytochrome P450, family 3, subfamily A, polypeptide 4 2.83 N/A 2.83 
CYP3A5 Cytochrome P450, family 3, subfamily A, polypeptide 5 0.59 0.77 -1.69 
DHFR Dihydrofolate reductase 1.07 0.75 1.07 
EGFR Epidermal growth factor receptor 0.59 0.90 -1.70 
ELK1 ELK1, member of ETS oncogene family 0.59 0.66 -1.69 
EPHX1 Epoxide hydrolase 1, microsomal (xenobiotic) 0.88 0.69 -1.14 
ERBB2 
V-erb-b2 erythroblastic leukemia 
viral oncogene homolog 2, 
neuro/glioblastoma derived 
oncogene homolog (avian) 
0.90 0.64 -1.11 
ERBB3 V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 0.53 0.70 -1.88 
ERBB4 V-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 0.15 0.02 -6.71 
ERCC3 
Excision repair cross-
complementing rodent repair 
deficiency, complementation group 
3 (xeroderma pigmentosum group B 
complementing) 
1.28 0.24 1.28 
ESR1 Estrogen receptor 1 1.21 0.77 1.21 
ESR2 Estrogen receptor 2 (ER beta) 0.54 0.02 -1.85 
FGF2 Fibroblast growth factor 2 (basic) 0.89 0.51 -1.12 
FOS FBJ murine osteosarcoma viral oncogene homolog 0.32 0.06 -3.16 
GSK3A Glycogen synthase kinase 3 alpha 1.35 0.52 1.35 
GSTP1 Glutathione S-transferase pi 1 0.69 0.49 -1.46 
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Symbol Description 
Fold 
Change T-TEST 
Fold Up- or 
Down-
Regulation 
MDA-MB-
231/PacR / 
MDA-MB-
231 
p-value 
MDA-MB-
231/PacR / 
MDA-MB-
231 
HIF1A 
Hypoxia inducible factor 1, alpha 
subunit (basic helix-loop-helix 
transcription factor) 
0.70 0.32 -1.44 
IGF1R Insulin-like growth factor 1 receptor 1.12 0.55 1.12 
IGF2R Insulin-like growth factor 2 receptor 1.35 0.23 1.35 
MET Met proto-oncogene (hepatocyte growth factor receptor) 0.40 0.07 -2.48 
MSH2 MutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) 1.69 0.12 1.69 
MVP Major vault protein 1.10 0.86 1.10 
MYC V-myc myelocytomatosis viral oncogene homolog (avian) 1.37 0.37 1.37 
NAT2 N-acetyltransferase 2 (arylamine N-acetyltransferase) 1.86 0.06 1.86 
NFKB1 
Nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells 1 
0.91 0.64 -1.10 
NFKB2 
Nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells 2 (p49/p100) 
2.44 0.02 2.44 
NFKBIB 
Nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells inhibitor, beta 
1.74 0.16 1.74 
NFKBIE 
Nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells inhibitor, epsilon 
1.50 0.18 1.50 
PPARA Peroxisome proliferator-activated receptor alpha 1.40 0.29 1.40 
PPARD Peroxisome proliferator-activated receptor delta 1.08 0.53 1.08 
PPARG Peroxisome proliferator-activated receptor gamma 1.39 0.00 1.39 
RARA Retinoic acid receptor, alpha 0.56 0.41 -1.78 
RARB Retinoic acid receptor, beta 2.61 0.00 2.61 
RARG Retinoic acid receptor, gamma 1.89 0.10 1.89 
RB1 Retinoblastoma 1 1.60 0.05 1.60 
RELB V-rel reticuloendotheliosis viral oncogene homolog B 1.40 0.59 1.40 
RXRA Retinoid X receptor, alpha 1.07 0.96 1.07 
RXRB Retinoid X receptor, beta 1.67 0.01 1.67 
SOD1 Superoxide dismutase 1, soluble 1.65 0.02 1.65 
SULT1E1 Sulfotransferase family 1E, estrogen-preferring, member 1 1.77 0.57 1.77 
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Symbol Description 
Fold 
Change T-TEST 
Fold Up- or 
Down-
Regulation 
MDA-MB-
231/PacR / 
MDA-MB-
231 
p-value 
MDA-MB-
231/PacR / 
MDA-MB-
231 
TNFRSF11A 
Tumor necrosis factor receptor 
superfamily, member 11a, NFKB 
activator 
3.11 0.00 3.11 
TOP1 Topoisomerase (DNA) I 1.42 0.03 1.42 
TOP2A Topoisomerase (DNA) II alpha 170kDa 1.29 0.17 1.29 
TOP2B Topoisomerase (DNA) II beta 180kDa 1.59 0.02 1.59 
TP53 Tumor protein p53 1.87 0.04 1.87 
TPMT Thiopurine S-methyltransferase 0.91 0.63 -1.09 
UGCG UDP-glucose ceramide glucosyltransferase 1.38 0.05 1.38 
XPA Xeroderma pigmentosum, complementation group A 1.82 0.36 1.82 
XPC Xeroderma pigmentosum, complementation group C 1.83 0.34 1.83 
ACTB Actin, beta 0.83 0.24 -1.21 
B2M Beta-2-microglobulin 1.11 0.37 1.11 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 0.94 0.66 -1.07 
HPRT1 Hypoxanthine phosphoribosyltransferase 1 0.82 0.07 -1.21 
RPLP0 Ribosomal protein, large, P0 1.41 0.07 1.41 
HGDC Human Genomic DNA Contamination - - - 
RTC Reverse Transcription Control - - - 
RTC Reverse Transcription Control - - - 
RTC Reverse Transcription Control - - - 
PPC Positive PCR Control - - - 
PPC Positive PCR Control - - - 
PPC Positive PCR Control - - - 
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